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CHAPTER I 
 
INTRODUCTION 
 
This work has been divided into six major chapters.  Chapter 1 provides a brief 
description of the organization of this dissertation along with a summary of the three 
major specific aims of this project.  Background information for virus detection strategies 
along with the significance of this project are described in Chapter II.  The bulk of this 
dissertation is comprised of three manuscript chapters, each corresponding to one of the 
specific aims.  Chapter III is my first report covering the basic aspects of my filament-
based virus detection system.  This manuscript was published in the September 20, 2005 
issue of Biotechnology and Bioengineering.  The second report on my virus detection 
system comprises Chapter IV.  This manuscript focuses on the successful development 
and implementation of an integrated fluorescence detector into my virus detection 
system, along with the incorporation of an adaptive feedback mechanism.  This 
manuscript was submitted for review to the Journal of Biomedical Optics in December, 
2005.  My final manuscript comprises Chapter V.  The focus of this final manuscript is 
the incorporation of a small set of human pathogens (reovirus) to show progressive 
detection of virus along a pre-programmed theoretical decision tree.  The manuscript 
describes a true feedback mechanism where current results are fed back to the control 
program to guide further testing to achieve specific diagnosis of virus subtype.  This 
manuscript will be submitted to the Journal of Immunological Methods in December 
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2005.  The final major chapter includes a brief write up of the potential applications for 
this technology, along with some future directions (Chapter VI). 
 
Specific Aims 
The major goal of this work was to develop a filament based virus detection 
platform that uses passively immobilized antibodies on the surface of a monofilament.  
The antibody regions are pulled through a series of reaction chambers where virus is 
detected with a fluorescently labeled second antibody, and the filament is scanned for 
fluorescence using an integrated detector.  This work was divided into three major design 
and development stages that are summarized below. 
 
Specific Aim 1: Design an automated virus detection platform using offline 
fluorescence detection and a single antigen/antibody pair 
 
The goal of this aim was to use a single virus/antibody pair to show that antibody 
probes could be immobilized on the surface of a monofilament and maintain their ability 
to capture target molecules out of solution.  This aim was separated into several major 
design issues: filament selection, probe immobilization, chamber design, reaction 
conditions, and filament control.  Selection of the optimal filament was critical for 
adequate probe attachment.  Several potential filaments were identified and were 
evaluated based on composition, size, autofluorescence, and solvent compatibility.  A 
polyester monofilament was a good choice for preliminary work.  Consistent deposition 
and attachment of probe to the chosen filament was an essential factor for achieving 
consistent and quantifiable results with my system.  Next, chamber design determined 
reaction volumes, diffusion distance, and fluid loss between adjacent reaction chambers.  
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Finally, automated filament control was necessary to minimize user intervention and 
allow easy programming of basic filament movement patterns. 
  
Specific Aim 2: Develop an integrated fluorescence detector and feedback 
controls 
 
The main goal of this aim was to develop an integrated fluorescence detector so 
that filaments could be immediately scanned following virus detection experiments.  
Online fluorescence detection allowed fluorescence data to be passed back to the control 
program for analysis, which enabled adaptive feedback control.  In this system, filament 
regions of interest were sent back through the reaction chambers for additional incubation 
if signal strength was inadequate.  We defined several hardware and software 
requirements to complete this aim of the project.  The choice of a suitable excitation light 
source, detector, filter sets, and digital acquisition board was the first step.  Software 
requirements included the ability to coordinate filament control with digital data 
acquisition, so that adaptive feedback was possible. 
 
Specific Aim 3: Characterize an unknown virus sample by incorporating a priori 
knowledge of antibody specificity to reovirus 
 
A pathogen with established subtypes that exhibit differences in protein 
expression and reactivity was needed to test the feedback and decision capabilities of this 
technology.  Reovirus provided a well-characterized pathogen with several known strains 
and serotypes.  Using a priori knowledge of differences in antibody affinity towards 
reovirus subtypes, a simple decision tree was designed that tested samples with different 
specificity, depending upon the results at each branch of the tree.  As a general strategy, 
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the specificity of testing progressed from low (top level of testing) to high (bottom level 
of testing).  The decision tree guided testing, so that in appropriate situations, 
unnecessary testing of every branch in the tree was avoided.  We identified a set of 
reoviruses and corresponding antibodies that were suitable to use in the decision tree. 
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CHAPTER II 
 
BACKGROUND 
 
Rationale 
 Recent media attention concerning the possibility of a world wide flu pandemic has 
brought to light many issues involving the preparedness of both local and national 
authorities to initiate an effective response to a viral outbreak.  In addition, many experts 
believe that a major threat to our country lies in the area of biological warfare due to the 
ease with which numerous deadly bacterial and viral agents can be obtained or produced 
(1-4).  The first step in mounting an effective response is fast and reliable detection of a 
wide variety of pathological agents.  Numerous laboratory techniques exist that, when 
used in conjunction with each other, can detect nearly any known human pathogen.  
However, none of these techniques is effective for all pathogens, and each has its own 
shortcomings.  A universal virus detection platform that can detect a wide range of 
pathogens with a high degree of sensitivity and accuracy is highly desirable 
 
Current Detection Methods 
 
Virus Culture and Microscopy 
Traditional culturing of virus in cells has been used for a long time for the growth 
and isolation of virus, but it still remains an important method of virus detection.  In fact 
there are many clinically important viruses that can be grown in just a small set of cell 
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lines.  This method typically involves infecting the cells and monitoring the characteristic 
cytopathic effect through light microscopy, but not all relevant viruses are easily cultured, 
such as hepatitis virus, Epstein-Barr virus, and HIV.  In addition, some viral antigens may 
remain with the host much longer than live, intact virus, so testing may need to be 
performed early in an infection before viral shedding becomes too low (5).  The 
significant time lag between infection of cells and diagnosis, along with limited 
sensitivity, are major reasons why this technique is losing ground to more sensitive 
molecular based techniques (1,6). 
Electron microscopy has the major advantage that it is theoretically able to detect 
all viruses directly in a sample or by the cytopathic effect on cells in a sample, making 
virus culture unnecessary.  But EM has very low sensitivity, requires a very expensive 
capital expenditure, and requires skilled personnel to make an accurate diagnosis. 
 
Serology 
 Serology is based on the fact that a humoral response will always follow an 
infection.  It is based on a rise in antibody titer from the beginning of an infection to the 
end, and serum collection typically is separated by at least 10-15 days.  ELISA is 
commonly used for serological testing, but typically the virus itself is immobilized in a 
microtiter well instead of an antibody.  Immobilized virus binds antibody from the 
sample and a labeled secondary antibody is used for detection.  Serology is typically used 
when other methods of virus detection are not feasible or effective or when viral shedding 
has reduced so much that other techniques are not effective.  Antibody response varies, 
but antibodies will be present in high amounts long after viral shedding has nearly 
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ceased.  The major drawbacks are the time delay between serum collections and the low 
sensitivity due to cross reactivity of many antibodies and antigens (5). 
 
Antigen Detection 
Immunofluorescence (IF).  IF typically utilizes a fluorescently or enzyme 
labeled anti-viral antibody to bind to the virus in a sample.  Detection can be done 
through absorption or fluorescence readings using a microtiter plate or fluorescence 
microscope.  These assays are typically quick (1-2 hrs) and are more sensitive than viral 
culture techniques.  However, a quality sample is needed due to cross reactivity of many 
antigens and antibodies.  IF is often used to diagnose respiratory viral infections such as 
respiratory syncytial virus (RSV), parainfluenza, and influenza using a nasopharyngeal 
aspirate.  Since viral antigens are displayed on the surface of epithelial cells for these 
viruses, at least a minimum number of cells is required for adequate detection.  This 
requires trained personnel to obtain and prepare a quality sample and, for some viruses, 
limits the sensitivity of this technique (5). 
 
Solid Phase Assays 
ELISA.  The enzyme linked immunosorbent assay (ELISA) is a widely used 
technique because of its simplicity and lack of expensive processing and detection 
equipment.  In a typical ELISA, a capture antibody is immobilized by passive adsorption 
into wells of a polymer microtiter plate and binds antigen in solution.  Next, a detecting 
molecule is added to each well that is coupled to a color-producing enzyme such as 
horseradish-peroxidase (HRP), followed by the addition of a chemiluminescent reagent.  
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ELISA is a very useful technique, but reagents are typically pipetted by hand into each 
well and a typical assay may utilize all 96 wells of a 96-well plate.  In addition, 
sensitivity remains poor compared to IF.  ELISA can be very time consuming and labor 
intensive, taking up to 12 hrs to achieve adequate signal.  As a result, experimental 
throughput is very low. 
Antibody Arrays.  Antibody arrays are able to probe in parallel for many viral 
antigens.  The theory of these arrays is similar to DNA arrays in that an array of 
antibodies is immobilized on the surface of a substrate, and a labeled target solution is 
washed across the surface to identify select components through antibody/antigen 
interactions. 
 Antibody arrays suffer from several shortcomings that have prevented their 
widespread use thus far.  Many commercially available antibodies are not suitable for use 
as probes due to lack of specificity and sensitivity.  Many antibodies will cross-react with 
numerous other cellular proteins, so signal intensity is not always directly linked to a 
specific protein abundance.  Finally, protein labeling can often interfere with its binding 
epitope, another factor that will limit antibody/antigen interactions (7).  Antibody 
selectivity must be greatly improved before antibody arrays can become a more integral 
tool for viral antigen detection (7). 
 
Nucleic Acid-Based Techniques 
PCR.   The polymerase chain reaction (PCR) has found widespread use in clinical 
and research settings because it can detect very low abundance molecules.  It has been 
reported that molecules with a copy number of only 1 molecule/ml have been detected, 
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but a typical PCR requires anywhere from 10-100 molecules (8).  The molecule of 
interest is amplified through repeated heating and cooling cycles in the presence of 
certain enzymes and excess nucleotide bases.  As a result, the sensitivity of PCR is 
unmatched by any other technique, but contamination by foreign DNA that is recognized 
by the same primers can create large background signals.  Analysis of final product is 
often done using a DNA gel or by hybridizing to a labeled complementary DNA strand. 
 Since all viruses contain DNA or RNA, PCR could, in theory, be used for any virus, 
but well designed primers are needed for effective amplification.  A good understanding 
of primer requirements is necessary since one primer may good for one variant of a virus 
but not another.  Primer designing software is available to aid in the development of good 
primers since secondary structure in a primer can prevent proper hybridization.  Real time 
PCR has been developed that monitors fluorescence produced as the amplification 
reactions proceed, which makes gel analysis unnecessary.  This process can be very fast 
and sensitive (5,6,9). 
 Another attractive feature of PCR is that active viruses are not needed, so sample 
transport and storage is less of a problem with this technique.  However, RNAses that are 
present can often damage sample.  Sample preparation is extremely important for PCR 
due to the extreme sensitivity of the technology.  Contamination from previous samples 
or environmental contamination is always a major concern.  As a result, dedicated PCR 
preparation areas and tools are required that are isolated from other laboratory functions 
are necessary to prevent contamination. 
DNA Arrays.  DNA microarrays are based on the sequence complementarity of 
the two DNA strands (10-14).  When separated, complementary DNA strands reassemble 
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with extraordinary accuracy.   The concept of using labeled nucleic acids in solution to 
interact with known probes attached to a solid support has been around for many years.  
With the incorporation of solid, non-porous supports such as glass, the process was easily 
miniaturized in the form of DNA microarrays (15,16).  DNA microarrays can be 
synthesized containing arrays of spots numbering from 10,000 to over 100,000 in one 
array (17-19).  DNA arrays could be an excellent way to probe for thousands of specific 
viral genes or gene segments, but sensitivity is not high enough to directly detect viral 
DNA.  Since sample preparation is required before hybridization can be performed, DNA 
microarrays are not as useful for directly probing biological fluids for viral nucleic acids. 
 
Limitations of current strategies 
Single molecule strategies.  Techniques such as virus culture, IF, PCR, and 
ELISA can be quite useful for identifying the presence of a small set of viruses or viral 
antigens within a sample.  These methods often require relatively inexpensive equipment 
and can be very effective when the required sample throughput is low.  However, when 
probing for an increasing number of viruses and viral antigens is required, these 
techniques become much less cost effective in terms of reagents and labor costs. 
Global detection strategies.  The purpose of global techniques is to probe for as 
many viral antigens or nucleic acid segments as possible in a single assay, but this 
approach does not come without a cost.  The requirement of higher sample volumes can 
be a critically limiting factor when using these techniques in a clinical setting where 
patient samples are limited.  Dynamic range is also a major problem of this all-in-one 
approach.  Since all spots are processed simultaneously under the same conditions, there 
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is no accommodation for low or high abundance targets.  Longer processing to detect low 
abundance molecules causes saturation of signal for high abundance molecules, which 
can mask surrounding spots; however, adjusting the processing for high abundance 
molecules limits detectability of low abundance molecules.  This limitation can 
sometimes limit the selection of molecules being screened with each technique.   
There is an inherent design flaw for array technology that sacrifices quick assay 
times for better sensitivity.  Current DNA and protein arrays are based on an approach 
where the probes are fixed in space and then exposed to target.  Since binding of probe to 
target requires direct contact, this approach is greatly limited by the slow diffusion of the 
target molecules across the surface of the array.  It has been shown that the diffusion 
coefficients for DNA and proteins in aqueous solution range from 10-6 to 10-7 cm2/s (20-
22).  For low abundance targets, it is imperative that each probe encounters each possible 
complementary target to achieve detectability.  However, the surface area of most arrays 
is far too great relative to the low diffusion coefficients for this to occur in a reasonable 
time frame.  In fact, in a typical overnight 12-hour incubation, diffusion of only a few 
millimeters occurs, so each probe will only interact with a small fraction of available 
targets.  This is a major factor that limits the sensitivity of these assays.  As a result, most 
assays require 20-50 µg of unpurified sample, which is often not feasible (23,24).  The 
typical sensitivity of DNA microarrays ranges from several hundred to a few thousand 
copies, depending on the assay, and protein arrays typically suffer from even worse 
sensitivity.  They often require many thousands of copies to achieve a detectable signal 
(BD Clontech, Ray Biotech technical data). 
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A high-density microarray with the capacity to contain 100,000 spots is overkill 
when a subset of only 50 structures has been identified as relevant for a particular 
situation.  Probing for irrelevant targets complicates data analysis and wastes time, 
money, and reagents.  Better techniques are needed to effectively and efficiently probe 
for known pathogen subsets that are too large for most single molecule detection schemes 
and too small for global detection strategies. 
 
Filament Based Virus Detection System 
This work describes a technology that takes an intermediate approach that directly 
probes for known viral subsets containing tens to hundreds of possibilities.  The system 
directly probes for known viral antigens using immobilized probes on a monofilament.  
Figure 3 (p.30), Figure 9 (p.55), and Figure 16 (p.90) show simple diagrams of our 
system.  A monofilament with antibody probes on the surface is pulled sequentially 
through a series of reaction chambers, one of which contains the unknown sample.  After 
a short incubation in that chamber, the probes on the filament are moved through 
subsequent chambers, washed, incubated with a detecting molecule, and washed again.  
After processing is complete, the probes of interest are moved through the detector where 
fluorescence of bound detecting molecule is measured.  The movement of the 
immobilized probes through each reaction chamber is controlled by a motor and 
computer interface.  The number of viral antigens that can be probed is limited only by 
the number of immobilized antibody spots on the filament. 
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Advantages of Filament Based System 
 
Reduced volume and diffusion distance 
 One of the most important consequences of the filament-based design is that 
diffusion distance required for target molecules to encounter probes is greatly reduced.  
Since the filament is pulled through the chamber, each probe encounters the entire axial 
length of the target solution.  The result of this filament movement is that target 
molecules need only to diffuse radially between the filament and the wall of the capillary.  
Using a small-bore glass capillary with an inner diameter of 300 µm with a 120 µm 
monofilament reduces the diffusion distance to 90 µm.  This distance is orders of 
magnitude smaller than the centimeter scale required for many techniques such as DNA 
and protein microarrays.  The calculated diffusion time at this scale could occur in 
minutes as opposed to the many hours required for larger scale systems. 
 Another consequence of the capillary reaction chamber is the ability to use very 
small sample volumes.  The volume of the capillary lumen is inherently very small, but 
filament running through the lumen reduces the volume even further.  For the dimensions 
described above, only one or two microliters of target solution is required to fill the 
chamber.  Typical DNA and protein arrays often require 50 µl or more for effective 
hybridizations.  The use of even smaller bore capillary tubes will reduce the diffusion 
distance and volume requirement even further. 
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 Automation and Feedback 
 The linear design of this system allows the incorporation of a unique automation and 
online feedback system that is impossible with other techniques.  The system of micro-
reaction chambers is attached to the top of a stage, and the filament is attached to a 
rotating axis.  The rotating axis is controlled through a LabView Virtual Instrument that 
winds and unwinds the filament to move the probe spots through each chamber and 
through the detector as desired (Figure 9).  The first chamber is a blocking chamber 
containing a low concentration of detergent that serves to prevent the bare filament from 
non-specifically binding virus or other proteins.  As the probes pass through chamber 2, 
they capture virus out of solution, followed by a quick wash in chamber 3 to get rid of 
any unbound virus.  Chamber 4 contains the detecting molecule that will bind to the 
captured virus, and chamber 5 provides a final wash to eliminate all unbound molecules 
from the filament.  Finally, the probe is moved through the detector where fluorescence 
of the detecting molecule is measured. 
 Since each probe can be processed and controlled independently, reaction conditions 
can be optimized for each different probe/target pair.  Processing of probes for targets 
expected to be in high or low abundance can be adjusted to keep signals detectable while 
keeping them all on the same scale.  This ability extends the dynamic range of the system 
so that it is much wider than other technique.  In addition, individual spot processing 
allows for a feedback system in which signal intensity must reach a pre-defined level 
before continuing to the next probe.  If measured signal is too low, that probe spot can be 
sent back through the reaction chambers for additional processing to improve signal to 
noise ratio. 
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Online feedback gives the system its most unique capability.  It allows our system 
to follow a pre-designed decision tree based on prior knowledge of virus and subtypes.  
In this design, the result from one antibody region determines which region will be 
processed next.  This eliminates unnecessary processing of probes that are shown to be 
irrelevant based on previous probes.  A simple example of this would be in the diagnosis 
of a particular subtype of an infectious agent.  The first set of probes determines the 
presence of absence of a general pathogen.  Following a positive result, probes that 
differentiate between pathogen subtypes are processed.  Using this strategy, each level of 
the decision tree further characterizes the virus in the sample.  This approach eliminates 
much of the unnecessary probing for irrelevant molecules. 
 
Initial Design Issues 
 
Probe Immobilization 
Many of the aspects of this technology are largely unexplored.  However, 
attachment of antibody probes to polymer substrates is one important aspect for which 
there is a considerable body of literature.  Many of these molecular recognition 
techniques such as DNA arrays, protein arrays, and ELISA require the immobilization of 
probes to the surface of substrates such as glass or various polymers.  Polyester filaments 
are similar to the polymers used in ELISA, so techniques used to immobilize proteins 
onto polymer substrates are of great interest.  Several methods have been characterized in 
the literature (25-27), and three have been shown to successfully immobilize antibodies 
on a polystyrene substrate.  These include passive physical adsorption through 
hydrophobic interactions, chemical immobilization on a polylysine coating, and non-
 
covalent linkage using a linker protein (protein G) that was passively adsorbed on the 
surface.  Each of these methods was shown to effectively immobilize antibody on the 
surface while retaining at least some of the antibody’s antigen capture ability.   
 Previous reports showed that antibody density on the polystyrene surface reached a 
maximum value as the concentration of antibody in the incubation solution increased past 
certain levels.  However, the maximum density of antibody using chemical linking to a 
polylysine coating was significantly higher than using the other two methods (25,26).  In 
studies of reactivity of immobilized antibody, there exist conflicting reports.  There is 
agreement that an optimal arrangement for antibodies on the surface is the “ends on” 
configuration where the Fc portion is bound to the support while the Fab portion is left 
free to bind antigen.  Schramm et al. have shown that for a particular antibody density, 
antigen binding is considerably lower for passively adsorbed antibody.  However, at 
increasing densities this discrepancy becomes smaller.  They hypothesize that at low 
antibody density, antibody binds in all configurations including “ends on”.  As density 
increases, attachment begins to favor the “ends on” attachment to maximize the amount 
of antibody that can bind. This helps to free the binding paratopes of the antibodies until 
the density reaches a point where steric hindrance between binding sites and between 
binding sites and antigens causes signal to decrease (Figure 1).   Non-passively adsorbed 
antibodies are already bound by their Fc region, so the proportion of available antigen 
binding sites does not change appreciably at higher densities.  Even at the highest density, 
non-passively adsorbed antibodies exhibit greater binding capacity possibly because of 
the flexibility imparted by such linking molecules.  The work of Butler et al. shows an 
even greater difference between passive and non-passive antibody adsorption.  Their 
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work estimates that as little as 3% of antibody binding site are available to bind antigen 
after physical adsorption, while up to 70% are available after immobilization using a 
chemical linker.  There is clear agreement that using a linker to immobilize protein 
results in greater activity of the enzyme or antibody, but the extent to which this is true is 
not clear.   
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 Figure 1:   Bound antigen increases with the immobilized antibody density until the 
density reaches a point where steric hindrance limits antigen interaction.  
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Virus Test System  
 M13K07 bacteriophage.  A major requirement for the development of this system 
was selecting a suitable virus test system that can show the full capabilities of our 
detection platform without any major safety concerns.  We chose a single 
antigen/antibody pair to show the initial automated virus detection during early 
development.  For this, we chose M13K07 bacteriophage due to availability and safety of 
this virus.  Anti-M13K07 monoclonal antibody is available commercially and has a very 
high affinity for the M13K07.  Since anti-M13K07 is a mouse IgG, it should display 
similar characteristics to other IgGs that will be used later for more complex testing.  
 In order to show clinical relevance of our system, later testing of our system required 
more than one virus/antibody pair so that the unique feedback capability could be 
demonstrated using a set of human pathogens.  Through collaborations with Terry 
Dermody in the Department of Pediatric Infectious Disease, we chose a small subset of 
reoviruses for testing.  
Reovirus.  We chose reovirus as a test system due to the expertise on this virus that 
was available to us, along with the availability of numerous reovirus types and subtypes.  
Antibodies showing differing levels of specificity toward each type and subtype were 
either available, or we were able to produce them using existing hybridoma lines.  The 
use of reovirus provided a human pathogen to show the detection and feedback 
capabilities of our system, while alleviating many of the safety concerns of most human 
pathogens. 
Reovirus is a non-enveloped virus containing 10 double stranded RNA segments.  
Although reovirus is able to infect mammals, it is rarely associated with adult disease.  
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Nevertheless, reovirus infection of newborn mice is one of the most commonly used viral 
models to study mechanisms of infection, pathogenesis, virulence, and viral tropism.  
Reovirus is both a respiratory and enteric virus, and these are the two known avenues for 
infection.  These routes of infection can lead to numerous diseases such as encephalitis, 
hydrocephalus, hepatitis, pneumonitis, and myocardis (28-31).  Viral spread throughout 
the host is one of two major pathways: spread through the nerves, or spread through 
lymphatics and the bloodstream to distant target organs.  Each of the predominant 
reovirus types favors one of these routes, but the mechanisms by which they differ are not 
completely understood. 
 The first viruses were isolated form the gastrointestinal tract of animals and humans, 
although they were not associated with disease in humans.  As a result, these viruses were 
given the name REO, which stands for respiratory enteric orphan virus.  Three serotypes 
have been identified based on their effect on hemagglutination of blood, and the 
separation of reovirus into these serotypes has been useful in predicting differences in 
pathogenesis.  In addition, each serotype is further characterized by the individual strain, 
and the four most common prototype strains, representing the three distinct serotypes, 
have all been isolated from humans: T1 Lang (T1L), T2 Jones (T2J), T3 Abney (T3A), 
and T3 Dearing (T3D). 
Reovirus Protein Coat.  Virions contain 11 different proteins that are encoded by 
10 discreet dsRNA segments of three distinct size classes.  Of these eleven proteins, three 
are not associated with the virus structure and are not well understood.  However, the 
remaining eight proteins have all been isolated, and their roles in reovirus infection have 
been studied extensively.  These eight structural proteins form two concentric, 
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intercalating shells, where each protein plays a specific role in reovirus infection.  The 
concentric shells are further defined by function.  The outer capsid gives the virion 
stability and is responsible for interaction with host cells, while the inner core plays a role 
in cell penetration, release of the viral genome into the host cell, and RNA transcription.  
Four major proteins comprise the outer capsid; however, a majority of the capsid 
is made of the σ3 and µ1 proteins, whose abundance on the outer surface is 
approximately 600 copies each.  The µ1 protein is thought to mediate virus attachment to 
host cells, while σ3 is thought to play an important role in the release of the virus 
subparticle once inside the cell.   Present at each of the twelve vertices of the icosahedral 
virion are pentamers of λ2, which are important during RNA synthesis.  The final major 
protein of the outer shell is the σ1 protein, a critical protein for the reovirus virion.  It has 
been closely linked to viral attachment to cells, along with other reovirus properties such 
as tropism within the nervous system, and different spreading pathways within the body. 
The remaining structural proteins make up the viral core and play different roles in virus 
infection and pathogenesis within the body.  There are still many interactions among the 
different reovirus proteins, as well as between viral proteins and the host cell that are not 
completely understood. 
Reovirus Selection and Antibody Specificity.   As a human pathogen, the use of 
reovirus gives clinical relevance to this virus detection platform.  Test viruses include 
T3D, T1L, T3SA+, and T3SA- because they represented two distinct serotypes along 
with two additional subtypes of serotype three.  As a well-characterized virus, antibodies 
have been created that display both serotype specific and non-serotype specific behavior.  
Reovirus antibodies that will be used for specific aim three are 9BG5, 5C6, 4F2, and 
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8H6.  While 9BG5 is specific for all serotype three reoviruses, 4F2 shows increased 
specificity for only T3D reovirus in our scheme.  5C6 is serotype one specific, and 8H6 
shows no serotype specificity.  This set of reoviruses and antibodies, along with the 
M13K07 and anti-M13K07, allowed us to design a three level decision tree to 
demonstrate feedback capabilities of our virus detection platform. 
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Abstract 
Two attractive features of ELISA are the specificity of antibody-antigen 
recognition and the sensitivity achieved by enzymatic amplification.  This report 
describes the development of a non-enzymatic molecular recognition platform adaptable 
to point-of-care clinical settings and field detection of biohazardous materials.  This 
filament-antibody recognition assay (FARA) is based on circumferential bands of 
antibody probes coupled to a 120 µm diameter polyester filament.  One advantage of this 
design is that automated processing is achieved by sequential positioning of filament-
coupled probes through a series of 25-60 µl liquid filled microcapillary chambers.  This 
approach was evaluated by testing for the presence M13KO7 bacterial virus using anti-
M13KO7 IgG1 monoclonal antibody coupled to a filament.  Filament motion first 
positioned the antibodies within a microcapillary tube containing a solution of M13KO7 
virus before moving the probes through subsequent chambers, where the filament-
coupled probes were washed, exposed to a fluorescently labeled anti-M13K07 antibody, 
and washed again.  Filament fluorescence was then measured using a flatbed microarray 
scanner.  The presence of virus in solution produced a characteristic increase in filament 
fluorescence only in regions containing coupled antibody probes.  Even without the 
enzymatic amplification of a typical ELISA, the presence of 8.3 x 108 virus particles 
produced a 30-fold increase in fluorescence over an immobilized negative control 
antibody.  In an ELISA comparison study, the filament-based approach had a similar 
lower limit of sensitivity of ~1.7 x 107 virus particles.  This platform may prove attractive 
for point-of-care settings, the detection of biohazardous materials, or other applications 
where sensitive, rapid, and automated molecular recognition is desired. 
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Introduction  
The enzyme linked immunosorbent assay (ELISA) is one of the most common 
antibody based molecular recognition assays in the laboratory, but the requirements of 
many clinical applications, where speed and throughput are critical parameters, have 
exceeded the capability of traditional plate-based ELISA.  Automated systems have 
overcome these limitations in large hospital settings and can process hundreds of samples 
per hour (32,33).  However, large integrated systems are not practical for point-of-care 
clinical settings where cost is a prohibitive factor.  In these settings, samples often are 
sent off-site for analysis, adding a significant time lag before results are in hand.  In many 
situations, the need for quick diagnosis and treatment make onsite testing very desirable.  
Many viruses are more easily treated when diagnosed early, so quick and reliable 
diagnosis that can be performed while a patient waits could allow treatment to begin 
immediately and, thus, improve the efficacy of treatment.  In addition to clinical testing, 
many field applications exist where rapid identification of a hazardous material is 
required to formulate an appropriate response. 
The generation of monoclonal antibodies and the advent of recombinant DNA 
technology have significantly increased both speed and sensitivity of molecular based 
assays (34,35).  A number of schemes based on the sandwich immunoassay have been 
reported in the literature.  For example, several recent applications are based upon 
changes in electrical properties as antigen binds to an immobilized probe (36-39) or 
based on the interaction of evanescent light waves with surface-bound antibodies (39-42).  
Many of these approaches are either labor intensive or require complex microfluidic 
devices and are not well suited for point-of-care clinical diagnostics or for field testing 
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for biohazardous materials.  A simpler antibody-based detection assay would be very 
desirable. 
This report uses a model bacteriophage/monoclonal antibody system to 
demonstrate a simple sandwich immunoassay that is based on immobilized antibody 
probes along a polyester monofilament.  M13K07 virus and anti-M13K07 IgG provide a 
simple test system for initial studies.  M13K07 is a harmless phage, so experiments can 
be performed with minimal safety concerns.  In addition, highly specific antibodies to 
M13K07 are commercially available, and binding between virus and antibody is well-
characterized.  The advantages of this approach include a reduction in reagent volumes 
and incubation times compared to standard ELISA, along with automation of the reaction 
process and elimination of the enzymatic amplification required in ELISA.  This paper 
describes the initial studies using this design and compares its sensitivity to traditional 
plate-based ELISA.  
 
Methods 
 
Reagents 
Anti-M13 monoclonal IgG1 (anti-M13) and anti-E tag monoclonal IgG1 (anti-E) 
were obtained from Amersham Biosciences (Piscataway, NJ) and fluorescently labeled 
with Alexa Fluor 647 (AF647), Alexa Fluor 555 (AF555) (Molecular Probes, Eugene, 
OR), Cy3, or Cy5 (Amersham Biosciences).  Labeling procedures were performed 
according to the manufacturers’ instructions.  The concentration of the labeled antibody 
along with the degree of labeling was calculated from the absorbance at 280 nm and the 
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peak label absorbance.  A working solution of labeled antibody was stored at 4°C, and 
aliquots were stored long term at –20 °C. 
M13K07 Virus (M13 virus) was obtained from the Vanderbilt Molecular 
Recognition and Screening facility in a stock concentration of 3.3 x 1011 virions/ml and 
was diluted in phosphate buffered saline containing 0.1 % tween-20 (PBS-T) to working 
concentrations immediately prior to experiments. 
 
Antibody Immobilization on Filament 
120 µm diameter clear polyester filament (440 yd spool, Sulky Invisible, Punta 
Gorda, FL) was obtained from webofthread.com (Kenmore, WA).  Glass, polyethylene, 
polyester, nylon, PVDF, and silk filaments were tested and rated based on 
autofluorescence at common wavelengths, flexibility, chemical composition, and 
strength.  The polyester filament provided the best combination of strength and flexibility 
and exhibited less intrinsic autofluorescence than the other polymer filaments.  In 
addition, polyester provided an excellent substrate upon which to passively adsorb 
antibodies.  The filament was wound around the ends of a PhastGel sample applicator 
(Amersham Biosciences) and placed within the concave teeth as shown in Figure 2.  
Combs were cleaned with a nearly saturated solution of NaOH in approximately 60% 
ethanol prior to winding the filament.  The comb/filament apparatus was washed in 70% 
ethanol, rinsed, washed in 10% HCl, and rinsed again. 
The filament was allowed to dry completely, and 0.75 µl of antibody solution was 
applied to each tooth of the comb.     
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 Figure 2:   Filament was wrapped around the ends of a gel loading comb and then placed 
across the concave teeth for antibody spotting. 
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In some assays, a low concentration of cytochrome C labeled with Cy3 protein label was 
added to the antibody solution (~2 µg/µl) as an indicator of antibody distribution.  The 
comb and filament were incubated in a humidified box for 45-60 minutes to allow time 
for adequate adsorption of antibody to the filament.  Following incubation, the comb and 
filament were immediately rinsed in PBS containing 0.1% tween-20 (PBS-T) to remove 
unbound antibody from the filament.  Filaments were used within two hours of this final 
rinse. 
 
Automated Virus Detection In Microcapillary Chambers  
A rotary stage and control system from Yaskawa (Waukegan, IL) were used to 
control the movement of the filament through five processing chambers.  The system of 
micro-reaction chambers was attached to the top of a horizontal stage using Lego 
building blocks.  This simple modular design allowed chambers to be easily repositioned 
or replaced.  Three sets of chambers were placed in parallel onto the horizontal stage.  
After each filament was threaded through the chambers, they were attached to a single 
rotating spindle on one end and small weights on the other.  In this manner, three 
filaments could be controlled in parallel with each other using a single interface.  The 
rotary stage was controlled through a LabView Virtual Instrument (National Instruments, 
Austin, TX) that wound and unwound the filament to maneuver the probe segments 
sequentially through each chamber as depicted in Figure 3. 
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Figure 3:   Capillary reaction chambers were arranged sequentially on a horizontal stage.  
A filament with antibody segments immobilized at known locations was threaded 
through the chambers.  One end was attached to the shaft of a precision rotary stage, and 
a small fishing weight was attached to the other.  The rotary stage controlled the 
movement of the antibody segments through each reaction chamber by winding and 
unwinding the filament. 
 30
The LabView interface controlled the speed of the filament through the chambers, 
oscillatory movements within the chambers, and total residence time within each 
chamber.  Filaments were oscillated 2 cm at a velocity of 0.5 cm/sec for the requisite time 
within each chamber before moving to the next.  Overall travel of the filament from the 
first chamber through the final was approximately 40 cm. Table 1 summarizes the 
contents and purpose of each chamber.  Chambers are separated by a distance of 1 cm, 
but contamination between chambers is a possibility.  Cross-contamination between 
microcapillary chambers was tested by placing labeled anti-M13 in one chamber 
followed by a chamber containing only PBS-T.  Mock processing was performed using 
typical filament motion parameters, and solutions from each capillary were collected and 
spotted onto glass slides for fluorescence scanning. 
To test for the consistency of virus detection, filaments were prepared with four 
distinct anti-M13 segments as described above.  The specificity of virus detection was 
tested by adding negative control segments to each filament.  Filaments were prepared 
with an alternating pattern of anti-M13 and anti-E that was not specific for M13 virus, for 
a total of four segments on each filament.  Labeled cytochrome C was not used as a 
positive control marker in these assays.    Reaction conditions for both experiments are 
summarized in Table 2.  To test the diffusion dependence of this system, virus incubation 
time was varied to examine the dependence of virus detection on antigen diffusion.  
Filaments were prepared with a negative control anti-E tag segment adjacent to five anti-
M13 segments.  Cy3-labeled cytochrome C was added to the spotting solution prior to 
filament preparation for a final concentration of approximately 2 µg/ml, serving as a 
positive control, so that spotted regions could easily be determined after scanning.   
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Table 1:  Contents and purpose of each reaction chamber. 
 Solution Purpose 
Chamber 1 PBS-T Rehydrate probes, block non-specific binding
Chamber 2 M13 virus Expose immobilized antibody to antigen 
Chamber 3 PBS-T Wash away unbound antigen 
Chamber 4 Labeled anti-M13 antibody Expose bound virus to labeled antibody 
Chamber 5 PBS-T Wash away unbound labeled antibody 
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Virus incubation time course experiments were done statically, and filaments were not 
oscillated within the virus chamber, but oscillation within other chambers was similar to 
previous experiments.  Table 2 summarizes the other reaction parameters for this assay.  
The effect of filament oscillation on virus detection was also tested.  A negative control 
segment was adjacent to four anti-M13 segments on each filament.  One set of filaments 
was oscillated within the virus chamber similar to previous experiments, while a second 
set was incubated using static conditions.  Additional reaction conditions are summarized 
in Table 2. 
 The sensitivity of virus detection was tested using larger capillary reaction chambers 
(1 mm ID, 60 µl).  In these experiments, filaments had a negative control segment 
adjacent to four anti-M13 segments.  Segments were incubated with 1.7 x 106, 1.7 x 107, 
1.7 x 108, 1.7 x 109, or 1.7 x 1010 virus particles in 60 µl PBS-T for 100 minutes.  The 
number of virus particles used in these experiments corresponded to the number of 
particles that was found to be detectable using plate ELISA.  The total assay time of 175 
minutes was 45 minutes less than the equivalent ELISA time.  Table 2 summarizes the 
other reaction conditions. 
 
ELISA 
 A standard criss-cross serial dilution analysis was performed to determine the 
optimal concentrations of immobilized capture antibody and detecting antibody (anti-
M13 conjugated to HRP) that yielded the highest sensitivity to virus.  50 µl of PBS was 
added to each well of a 96 well ELISA plate.   
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Table 2:  Summary of reaction parameters used in each experiment. 
Experiment  
Consistency 
of virus 
detection 
Specificity 
of virus 
detection 
Diffusion 
Dependence 
Effects of 
Filament 
Oscillation 
Detection 
Sensitivity 
Chamber 1 10-15 min 10-15 min 10-15 min 10-15 min 10-15 min 
Chamber 2 35 min 45 min 25-990 min 45 min 100 min 
Chamber 3 5 min 5 min 5 min 5 min 5 min 
Chamber 4 35 min 45 min 45 min 45 min 50 min 
Chamber 5 10 min 10 min 10 min  10 min 10 min 
Oscillation 2 cm, 0.5 cm/sec 
2 cm, 0.5 
cm/sec 
None in virus 
chamber 
2 cm, 0.5 
cm/sec 
2 cm, 0.5 
cm/sec 
Chamber 
Volume 25 µl 25 µl 25 µl 25 µl 60 µl 
Virus 
Particles 8.3 x 10
8 8.3 x 108 8.3 x 108 8.3 x 108 1.7 x 10
7 – 
1.7 x 109 
Labeled 
Antibody 
40-50 µg/ml 
AF555 anti-
M13 
40-50 µg/ml 
AF555 anti-
M13 
40-50 µg/ml 
AF647 anti-
M13 
40-50 µg/ml 
AF647 anti-
M13 
40-50 µg/ml 
AF647 anti-
M13 
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Next, 50 µl of unlabeled anti-M13 (50 µg/ml in PBS) was pipetted into column 1 and 
serially diluted 1:2 through column 11, leaving column 12 with only PBS.   The plate was 
incubated for 1 hour at room temperature in a humidified box, rinsed 3 times with PBS-T, 
and blocked with 50 µl PBS-T for 15 minutes.  After blocking, 50 µl of virus solution 
(3.3 x 1010 virions/ml) was added to each well, and the plate was incubated for another 
hour in a humidified box, followed by 6 rinses with PBS-T.  50 µl PBS-T was added 
again to each well of the plate.  HRP-conjugated anti-M13 was diluted 1:500 in PBS-T, 
and 50 µl was added to each well in the first row of the plate.  The antibody was then 
serially diluted 1:2 through row G, leaving row H with PBS-T only.  The plate was then 
incubated for 1 hour in a humidified box and rinsed.  To develop the plate, 50 µl of the 
HRP substrate (50 mM sodium citrate buffer, pH4.2, containing 90 mM ABTS and 0.05 
mM H2O2) was added to each well and left at room temperature.  Absorbance readings 
were taken using a microplate reader (405 nm) at both 20 minutes and 75 minutes, and 
the signal to noise ratios were calculated by dividing the raw values with the 
corresponding negative control values in column 12.  Optimal concentrations for capture 
antibody and HRP-conjugated detecting antibody were found to be 1.56 µg/ml and 
1:2000 dilution, respectively. 
 ELISA experiments using the optimized values for primary and detecting antibody 
were performed to determine the sensitivity of this assay to M13 virus.  The ELISA 
plates were processed as described above.  Additional wells containing virus of each 
concentration were added in duplicate into the wells of column 7 for use as negative 
controls.  Signal to noise ratios were determined as described above. 
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Reagent Testing 
 Preliminary experiments and optimization of immobilized antibody were performed 
using antibody-filament reactions in 2 ml Eppendorf tubes in place of capillary reaction 
chambers.  After blocking in PBS-T for 10 minutes, the filaments were transferred to a 
virus solution (3.3x1010 virions/ml) and gently rocked on an orbital shaker for 30 
minutes.  After a 5 minute wash in PBS-T, the filaments were again removed and placed 
in a solution of anti-M13 labeled with either Alexa Fluor 647 or Alexa Fluor 555 protein 
label (~10 µg/ml in PBS-T) and were gently rocked for an additional 30 minutes.  After a 
final wash of 10 minutes in PBS-T, the filaments were scanned for fluorescence.  Due to 
the relatively large volume used for Eppendorf processing, the amount of virus used was 
approximately 50 times greater than automated, capillary chamber experiments. 
 
Detection and Analysis 
  Following all experiments, filaments were removed after the final wash, taped to 
glass microscope slides, and scanned in a GenePix 4000B microarray scanner (Axon 
Instruments, Union City, CA).   Due to the three dimensionality of the filament, a series 
of scans on a single filament was obtained at different focal depths to determine the scan  
depth for maximum fluorescence.  A 75 µm depth of focus yielded the strongest signal, 
so all subsequent filaments were scanned at this depth.  Filaments were scanned using 
both the 532 nm and 635 nm wavelengths of the scanner, and segment fluorescence and 
background fluorescence were quantified (Image Pro 4.0, Media Cybernetics, San Diego, 
CA) by taking the average pixel fluorescence over the segment area.  Fluorescence 
images from the microarray scanner were artificially rendered green or red by the 
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scanning software to better distinguish the 532 nm and 635 nm wavelengths of the 
device.  To determine the signal to noise ratio of each experiment, fluorescence of anti-
M13 segments was divided by the background fluorescence or negative control 
fluorescence if a negative control was present.  Analysis of variance of fluorescence 
signals and background signals was used to determine statistical significance (p<0.05). 
 
Results 
Figure 4 shows a typical fluorescence pattern after detection of M13 virus during 
reagent testing experiments.  This experiment shows little or no detectable cross 
reactivity between M13 virus and a non-specific anti-E antibody.  Immobilized segments 
one and two (left side of Figure 4) are each labeled with a different fluorescent tag and 
serve as positive controls for each wavelength.  These segments should fluoresce at their 
corresponding wavelengths under all conditions.  Segment three is an anti-E tag 
monoclonal antibody that is not specific for M13 virus and serves as a negative control.  
This region should not bind virus or detecting antibody and, therefore, should not 
fluoresce under any conditions.  Segments four, five, and six contain unlabeled M13 Ab 
and should fluoresce only if virus is present.  Holding all other parameters constant, 
filament oscillation within the virus chamber was also tested to determine whether it 
increases segment fluorescence over a static virus incubation.   
Using a static incubation, the average signal to noise ratio for each of three 
filaments (each with four segments) is 1.4, 1.2, and 2.0 (avg = 1.5).  Filament oscillation 
increased the average signal to noise ratio nearly 5 times to 5.6, 6.6, and 8.8 (avg = 7.0).  
After subtracting intrinsic fluorescence of the filament at the appropriate wavelengths 
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from all spotted regions, signal to noise was defined as the average fluorescent signal of 
anti-M13 regions divided by average fluorescence of negative control regions.  When a 
negative control was not present, signal to background was used to judge the success of 
the experiment.  In these circumstances, average fluorescent signal of anti-M13 regions 
was divided by average fluorescence of empty regions on the filament that were 
processed in the same manner as the anti-M13 regions.  These experiments suggest that 
filament oscillation leads to an increase in virus interaction with the filament-bound 
antibody.    
After appropriate reaction conditions were identified, the effectiveness of 
automated filament movement through microcapillary chambers was evaluated.  To 
determine detection repeatability, four filaments each with four immobilized anti-M13 
segments were prepared, threaded through the system of capillary chambers, and filament 
motion was programmed into the LabView virtual instrument.  The top panel in Figure 5 
shows both the fluorescence pattern obtained from the filament scan of one filament and 
the average segment fluorescence of each segment.  Comparison of four filaments, each 
with four segments, yielded an overall average for all sixteen segments of 10542 ± 1374 
(mean ± SD) and an overall coefficient of variation (CV) of 0.13.  Intra-assay CV for 
individual filaments varied from 0.05 to 0.4. 
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Figure 4:   Immobilized anti-M13 detects the presence of M13 virus in solution.  
Segments 1 and 2 are fluorescently labeled positive controls and segment 3 shows the 
level of cross-reactivity with a non-specific negative control antibody.  Segments 4-6 
show virus detection in solution. 
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Detection specificity was also evaluated.  For these experiments, three filaments 
were prepared with patterns of four alternating segments of unlabeled anti-M13 and 
unlabeled anti-E as a negative control.  The bottom panel in Figure 5 shows the 
florescence pattern and the average segment intensities from one of these experiments.  In 
this experiment, signal from anti-M13 segments is approximately 40 times greater than 
the negative control anti-E segments.  The overall average results from all three filaments 
in this set were ~30 times greater for anti-M13 segments (16264 ± 5396) than negative 
control segments (573 ± 278).  Overall CV for anti-M13 and negative control signals was 
0.33 and 0.48, respectively.  Intra-assay CV calculations were not possible since only two 
segments of each type were present on each filament.  A direct fluorescence comparison 
between reproducibility and specificity graphs is not possible since all parameters were 
not the same for each test.  These experiments provide strong evidence that this system 
consistently and specifically detects virus in solution with a high signal to noise ratio 
compared to a non-specific antibody. 
Since immobilized antibody concentration significantly effects sensitivity of 
standard ELISA, an experiment was performed to determine the optimal spotting 
concentration of anti-M13 for the filament based system.  Anti-M13 of varying 
concentrations was spotted and immobilized on a filament and then processed through 
capillary reaction chambers to determine which concentration gave the strongest signal.   
A negative control anti-E segment was adjacent to increasing concentrations of anti-M13 
spotting solution, and the filament was processed through capillary reaction chambers 
using parameters similar to previous virus detection experiments.   
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 Figure 5:   Typical fluorescence patterns and average fluorescence of immobilized probe 
segments, showing repeatability (top) and specificity (bottom).  Fluorescence varies by 
approximately 5% between segments (top), and fluorescence from anti-M13 segments is 
approximately 40 times greater than negative control anti-E segments (bottom). 
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As Figure 6 illustrates, the data shows an increase in signal intensity up to 600 µg/ml, 
after which the signal begins to drop, a trend that is consistent with the literature for 
antibodies immobilized on other polymers (25). 
 Antigen-antibody sensitivity was determined using a traditional ELISA.  Three 
ELISAs were run to determine the lower limit of detection of M13 virus with anti-M13 
antibody.  The number of virus particles ranged from 1.7 x 104 to 1.7 x 109, and each 
assay included 8 trials for each condition.  The lowest number of virus particles that 
yielded a statistically significant signal was 1.7 x 107 (p<0.05) (Figure 7). 
Experiments were performed to determine the lower limit of sensitivity of this filament-
antibody recognition assay (FARA) approach.  Five filaments, each containing four 
distinct M13 Ab segments and one negative control anti-E segment, were incubated with 
five different virus copy numbers comparable to virus numbers detected with standard 
ELISA.  Incubation times for virus and detecting antibody were 100 min and 50 min, 
respectively, so that total assay time for automated filament based detection (~175 
minutes) was 20% less than the ELISA (~220 min).  These approximate assay times 
include all washing steps and ELISA developing time but do not include filament or 
ELISA preparation time.  As shown in Figure 7, the filament based assay detected similar 
amounts of virus with similar signal to noise ratios as standard ELISA.  Diffusion of the 
virus to the filament surface may be a major factor that limits detection sensitivity with 
the FARA approach.  Figure 8 shows results from a time course of virus incubation time.  
Fluorescence intensity increases with virus incubation time, which is consistent with the 
hypothesis that diffusion/delivery of virus is an important factor.  However, our data 
suggests that other factors contribute as well, since signal intensity is not proportional to 
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the square root of the incubation time.  Nevertheless, virus incubation time appears to be 
a critical parameter.   
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Figure 6:   Fluorescence intensity increases with spotting solution concentration up to 
about 500 µg/ml.  At concentrations above this point, intensity begins to decrease. 
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Figure 7:   Detection and calibration curve for both FARA (closed circles) and ELISA 
(open circles).  Both methods have a lower limit of sensitivity of ~1.7 x 107 virus 
particles.  Data points represent SNR obtained for different virus copy numbers (mean ± 
SD, n=3 experiments for ELISA and 4 spotted regions for FARA);  *indicates 
significantly increased signal over negative controls  
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Figure 8:   Signal strength increases with virus incubation time (mean ± SD, n=3). 
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Discussion 
These data demonstrate that anti-M13 antibody can be passively adsorbed to a 
polyester filament, and the antibody remains functional.  Direct binding is shown by the 
hydrophobic attachment of fluorescently-labeled control antibody (Figure 4).  Indirect 
evidence suggests that binding sites on filament-immobilized antibodies remain active 
and capture virus out of solution (Figure 4, Figure 5, Figure 6, Figure 7, Figure 8).  The 
addition of tween-20 to the wash solution after initial capture antibody attachment 
appears to effectively block further non-specific filament-antibody interaction.  This is 
supported by the observation that the fluorescently-labeled second antibody does not 
directly interact with the filament, as shown by the non-fluorescent regions between 
immobilized segments.   
The lower limit of sensitivity of this assay was similar to a traditional plate 
ELISA.  The limit of sensitivity of the FARA approach is 1.7 x 107 particles (~400 pg), 
which is similar to the limit of traditional ELISA (Figure 7).  This level of sensitivity was 
achieved in a shorter assay without the required amplification step for ELISA and with 
automation of the reaction process.  The detection area for one spot using the FARA 
approach is approximately 7.5 x 105 µm2 (d=120 µm, l=2000 µm)  FARA detects 1.7 x 
107 particles, which means that at the lower limit of sensitivity, FARA detects 22.5 virus 
particles/µm2.  A similar calculation shows that a single well in an ELISA with a much 
larger detection area of approximately 3.8 x 106 µm2 (d=0.7 cm) has a detection 
sensitivity of only 0.44 virus particles/µm2.  Using this measure, FARA is approximately 
50 times more sensitive per unit area than ELISA.   
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Exact calculation of mass transfer coefficients for each system can not be made, 
but the ratio of the coefficients can be estimated by making some assumptions.  The total 
amount of virus transferred per unit time can be calculated by multiplying the mass 
transfer coefficient (k), the detector surface area (A), and the virus concentration (C).  
The total amount of virus transferred can be calculated by multiplying the product kAC 
by the total virus incubation time (T).  From Figure 6, both assays produced similar 
signal to noise ratios using 107 to 108 virus particles.  If the assumption is made that equal 
numbers of virus particles are transferred to the surface within this range of virus 
particles, the ratio of the mass transfer coefficients is estimated as:  kF/kE = 
cEAETE/cFAFTF, where the subscripts E and F denote ELISA and FARA.  Since 
concentration, area, and assay times are known values, this ratio is approximately 3.  
Several assumptions were made in this calculation that need to be further verified. 
Although FARA sensitivity is similar to ELISA, adding an amplification step may 
increase sensitivity even further.  Precipitating substrates used in ELISA may be an 
attractive amplification method in this system, as well, but it is not clear whether the 
precipitant could be confined to each spotted region as filament processing continued.  If 
precipitants became dissociated from specific regions, detection of individual regions 
would not be possible.   
 The microcapillary geometry of the FARA approach may account for the high 
sensitivity observed.  The linear geometry of the microcapillary chambers combined with 
filament motion reduces the diffusion distance required for target molecules to encounter 
immobilized probes.  In this system, probes can be slowly oscillated within a reaction 
chamber, allowing the immobilized probes to query the entire axial length of target 
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solution.  As a result, the limiting diffusion distance is the radial distance from the 
filament to the edge of the chamber.  The current size of the capillary chambers is 
approximately 700 or 1000 µm ID.  Since the filament diameter is 120 µm, the radial 
diffusion distance is either 290 µm or 440 µm, which is an order of magnitude less than 
the diameter of a 96-well ELISA plate.  Based on values reported in the literature for 
large proteins, the virus diffusion coefficient was estimated to be on the order of 10-8 
cm2/sec (20,21).  Assuming the simple diffusion relationship of Dtd 2= , diffusion of 
290 µm would still take nearly 700 min.   Much smaller capillaries are available that 
could reduce this distance to well under 100 µm, a distance over which diffusion could 
occur much more quickly.  Although this distance is still too great for target molecules to 
completely diffuse under reasonable incubation times, it is much smaller than the 
distance required in a plate based assay. 
A possible complication arising from the filament motion and open geometry of 
the capillary reaction chambers is fluid contamination between chambers.  However, 
cross-contamination experiments showed that contamination is minimal and is less than 
4% between chambers.  The addition of extra wash chambers is an easy solution, which 
could be used to further reduce carry over between adjacent chambers.  
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Abstract 
 We recently reported the development of a filament-antibody recognition assay 
(FARA)(43) which, through the use of antibodies coupled to a moveable filament, detects 
the presence of virions by building an ELISA-like antibody-antigen sandwich attached to 
a filament.  In this report, we combine the motion of the filament with a fixed laser-based 
optical detector to enable real-time controlled detection of virions in solution.  A 638 nm 
laser with a photomultiplier at a right angle provided continuous monitoring for the 
presence of the anti-M13 monoclonal IgG2a labeled with Alexa Fluor 647.  Entrainment 
of this labeled antibody was indicative of virus captured by unlabeled anti-M13 
previously coupled at known locations along the filament.  As expected, as virus 
incubation time increased, lower concentrations of virus were detectable. A one-minute 
incubation was required to detect 1010 virions and 40 minutes was required to detect 108 
virions.  Since fluorescence intensity is measured in real-time, this information can be 
used to position the filament. Therefore, an unknown virus sample can be subjected to 
both a rapid initial test and then, if necessary, a slow follow-up high sensitivity test.  In 
tests of the feasibility of this approach, a thirty minute virus (3.3 x 1010 virions/ml) 
incubation time followed by recycling the captured virus to the detecting antibody 
chamber (20 µg/ml) found an increase in signal roughly proportional to the 0.5, 1, and 2 
minute residence times in the detecting antibody chamber.  Tests of recycling capture 
antibody regions to the virus chamber (3.3 x 1010 virions/ml) for cumulative virus 
incubation times of 1, 5, or 10 minutes followed by an additional 1 minute detecting 
antibody (20 µg/ml) incubation also found an increase in signal proportional to the virus 
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incubation time.  Filament positioning combined with on-line optical detection provides 
new flexibilities for developing adaptive molecular recognition assays. 
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Introduction 
 The need for fast, reliable, and cost effective pathogen detection is increasing as a 
result of both increasing health care costs and the rising threat of bioterrorism.  
Traditional methods, which can often be completed using existing laboratory 
infrastructure and equipment, are still the most reliable and robust techniques and can 
used to detect a broad range of pathogens.  However, these techniques require highly 
trained laboratory personnel and can be both labor and time intensive.  Since these 
methods typically involve growth of the organism in culture or infection of a virus in a 
suitable host, these techniques may require days before identification of the hazard is 
complete (34,44). 
 Immunological methods have been developed that encompass a very broad range of 
applications such as the detection of bacterial cells, spores, viruses, proteins, or any other 
toxin that elicits an immune response (34,44,45).  Numerous new immunological 
detection strategies have been reported in the literature, and several reviews have been 
written summarizing the state of the art of immunological biosensors (34,46,47).  Several 
of these methods are based upon changes in electrical properties as antigen binds to an 
antibody coated substrate (36,37,47-49).  Many others have been reported that 
incorporate optical detection of bound antigen.  For example, evanescent waves have 
been used to excite bound antigen on a fiber optic waveguide using a fluorescently 
labeled detecting antibody.  Ligler et al., have extended this technique to incorporate a 
two dimensional waveguide upon which an entire array of probe molecules has been 
immobilized (40-42).  However, many of these assays require complex microfluidics, and 
automation of fluid handling and processing is very difficult to incorporate into these 
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systems.  In addition, these optical techniques usually lack a feedback mechanism to 
determine when the experimental signal has reached an adequate level.  Rather, these 
assays must be run to completion in order to ensure sufficient signal, wasting time, 
reagents, and sample. 
 We have recently reported the development of a filament-antibody recognition assay 
(FARA).  In this report, we incorporate an integrated optical detection method to enable 
optical feedback control of virus detection.  FARA is a sandwich-based immunoassay in 
which antibodies are immobilized on the surface of a monofilament rather than on a 
polystyrene plate.  Using a rotary stage to control filament position, each antibody 
bearing region is passed through a series of five fixed reaction chambers (Figure 9).  The 
first chamber washes excess antibody from the filament uses a non-ionic detergent to 
block non-specific binding in subsequent steps.  Antibody regions are exposed to the 
unknown virus solution in the second chamber and bind virus out of solution, if the 
corresponding virus is present.  After a brief wash in the third chamber, the antibody 
regions are exposed to a fluorescently-labeled detecting antibody that will bind to virus 
on the filament that has previously been captured from solution.  Following a final wash 
to remove any unbound reagents, the antibody regions on the filament are passed through 
an integrated detector where the fluorescently-labeled detecting antibody is excited with a 
diode laser.  Fluorescence from the detecting antibody is detected by a photomultiplier, 
and the signal values are used to determine if additional testing or further processing is 
required.  
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Figure 9:   Filament-coupled antibodies are pulled through a series of five reaction 
chambers before passing through a fluorescence detector.  Detection of filament-bound 
virus is achieved through a fluorescently-labeled detecting antibody that is excited with a 
diode laser.  Fluorescence is detected by two photomultiplier tubes. 
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Materials and Methods 
 
Antibody and Virus reagents 
M13K07 phage and anti-M13 monoclonal antibody provide a suitable model 
system for this design, but nearly any antibody/antigen system would be suitable for this 
approach.  However, M13K07 is a harmless phage that is well characterized, so assays 
can be performed with minimal safety concerns. M13K07 Virus (M13) was obtained 
from the Vanderbilt Molecular Recognition and Screening facility in a stock 
concentration of 3.3 x 1011 virions/ml and was diluted in phosphate buffered saline 
containing 0.1 % tween-20 (PBS-T) to working concentrations immediately prior to 
experiments.  Anti-M13 monoclonal IgG2a (anti-M13) and anti-E tag monoclonal IgG2a 
(anti-E) were obtained from Amersham Biosciences (Piscataway, NJ) and fluorescently 
labeled with Alexa Fluor 647 (AF647, Molecular Probes, Eugene, OR). Labeling 
procedures were performed according to the manufacturers’ instructions.  The 
concentration of the labeled antibody along with the degree of labeling was calculated 
from the absorbance at 280 nm and the peak label absorbance.  Aliquots were stored long 
term at –20 °C, and working solutions of both labeled and unlabeled antibody were stored 
at 4°C. 
 
Antibody Immobilization on Filament 
Antibodies were passively adsorbed to a clear polyester filament with a diameter 
of 120 µm (Sulky Invisible, Punta Gorda, FL).  The filament was wound around the ends 
of a PhastGel sample applicator (Amersham Biosciences) and placed within the concave 
teeth as described previously (43).  The comb/filament apparatus was washed in 70% 
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ethanol, rinsed, washed in 10% HCl, and rinsed again.  The filament was allowed to dry 
completely, and 0.75 µl of capture antibody solution (500 µg/mL) was applied to each 
tooth of the comb.  To allow time for adequate adsorption of the capture antibody to the 
filament, the comb and filament were incubated in a humidified box for 45 minutes.  
Following incubation, the comb and filament were immediately rinsed in PBS containing 
0.1% tween-20 (PBS-T) to remove unbound capture antibody from the filament.  
Filaments were used within one hour of the final rinse. 
 
Filament Processing  
 One-quarter inch (OD) thick-walled glass capillary tubing was cut into 75 mm 
lengths, and the ends were flared outward to facilitate smooth movement of the filament 
in and out of the chambers.  Table 3 summarizes the contents and function of each 
chamber.  Each glass chamber was housed in an aluminum holder with holes for two 
positioning bolts as shown in the inset of Figure 9.  A horizontal aluminum stage with a 
matrix of predrilled holes allowed the chambers and holders to be easily aligned and 
fastened.  After a filament was threaded through the chambers and detector, it was 
attached to a rotating spindle atop a rotary stage on one end and a small weight on the 
other as shown in Figure 9.  
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Table 3:  Contents and description of each chamber. 
Chamber ID 
(mm) 
Solution Function 
1 2 PBS-T Rehydrate probes, block non-specific 
binding 
2 0.75 M13 virus Expose immobilized antibody to antigen 
3 2 PBS-T Wash away unbound antigen 
4 0.75 Labeled anti-M13 
antibody 
Expose bound virus to labeled antibody 
5 2 PBS-T Wash away unbound labeled antibody 
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Filament movement through the five chambers and detector was performed using the 
rotary stage and control system from Yaskawa (Waukegan, IL).  The rotary stage was 
controlled through a LabView Virtual Instrument (National Instruments, Austin, TX) that 
wound and unwound the filament to position the probe segments sequentially through 
each chamber.  The LabView interface controlled the speed of the filament through the 
chambers, oscillatory movements within the chambers, and total residence time within 
each chamber.  Filaments were oscillated 2 cm at a velocity of 1 cm/sec for the requisite 
time within each chamber before moving to the next.  Overall travel of the filament from 
the first chamber through the detector was approximately 50 cm. 
 
Fluorescence Detection 
 A laser excitation source was used to excite a fluorescently labeled detecting 
antibody specific for the bound M13 virus.  The detection system incorporated two diode 
lasers at a 90° orientation to the filament.  The dual laser design allowed for flexibility 
when choosing appropriate fluorescent labels for detection.  The filament ran through a 
detection chamber (Newport-Oriel, Stratford, CT) that allowed easy coupling of two 
lasers and two PMTs.  Figure 9 shows a diagram of the virus detection scheme.  Laser 1 
was a 25 mW, 638 nm diode laser (Coherent, Santa Clara, CA) and was used to excite the 
AF647 fluorescent dye.  Laser 2 was a 532 nm, 20 mW diode-pumped, solid state laser 
(B&W Tek, Inc., Newark, DE) that was used to excite AF555 fluorescent dye, which was 
used primarily in preliminary experiments.  The detector’s dual laser and dual PMT 
design allows for two fluorescent labels to be used concurrently, adding flexibility to this 
technique. The lasers were attached to the detection chamber on either side using custom 
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adaptors to fit the ports of the chamber.  A polarizer was placed within the adaptor to 
reduce the 638 nm laser power to approximately 5 mW.   
 The PMTs were also attached via custom adaptors to the top and bottom of the 
chamber.  Reflectance of the laser light from the filament was a significant issue, so 
choice of emission filters was critical to achieving a high signal to noise ratio (SNR).  For 
the AF647 channel, long pass filters with cutoffs at 685 nm (Chroma, Rockingham, VT) 
and 665 nm (Melles Griot, Rochester, NY) were combined to filter out reflected laser 
light.  The AF555 channel combined a bandpass filter centered at 565 nm (30 nm 
bandwidth, Chroma) with a long pass filter (570 nm cutoff, Melles Griot) to filter out 
reflected light.  Filters were placed in between the sample chamber and the PMTs as in 
Figure 10. 
 Figure 10 shows the optical path for our detector.  A custom metal slit was fashioned 
out of brass and placed in the laser path, to minimize the area on the filament illuminated 
by the laser.  After exciting bound detecting antibody, fluorescence emission from the 
detecting antibody passes through a pinhole that reduces much of the reflected laser light.  
The light then passes through a pair of emission filters, which removes the excitation 
light, while allowing fluorescence to pass through to the PMT (R928, Hamamatsu).  Each 
PMT was powered by an 800 V signal and the resulting current was converted to voltage 
and amplified by a factor of 105 by a transimpedance amplifier.  The amplified voltage 
(0-14V) was sampled by a digital acquisition board (National Instruments) that was 
controlled through a LabView virtual instrument.   
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Figure 10.  Optical path of virus detection system.  Using a 638 nm laser excitation 
source, detection of filament fluorescence is possible using the appropriate emission 
filters.  Exposure area on the filament is reduced by an excitation slit. 
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Filament movement and signal sampling were synchronized using a single LabView 
interface.   Positive virus detection is defined as p < 0.05 for an unpaired t-test of capture 
antibody regions compared to control regions. 
 
Experimental Parameters 
Filament movement parameters were consistent throughout all experiments.  
Filament regions were oscillated back and forth 2 cm at 1 cm/s within each chamber for 
the requisite length of time, and filament speed in between chambers was constant at 2 
cm/s.  All filaments were blocked in Chamber 1 for 15 minutes before experiments were 
started.  All experiments used M13K07 virus (3.3x1010 virions/ml, unless otherwise 
noted) and used AF647 anti-M13 (20 µg/ml) for detection.  Virus detection experiments 
differed only by incubation and wash times.  SNR was defined as the average peak height 
of anti-M13 regions divided by average peak height of a negative control anti-E region. A 
standard unpaired t-test was used to compare average peak values with average anti-E 
values to determine statistical significance.  P values less than 0.05 signified positive 
virus detection. 
Basic system tests were performed to show the effectiveness of our optical system 
and to determine some standard parameters that help optimize signal to noise (Table 4).  
These tests were designed to show that FARA was capable of a high SNR and to show 
that laser exposure did not significantly bleach our labeled detecting antibody.  
Qualitative observations using our laser at full power (25 mW) previously showed that 
bleaching effects may be greater when the filament is still wet.  To show that this effect 
was minimized with a less powerful laser beam, multiple laser scans of the same filament 
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were performed after a typical virus detection experiment.  The filament was first 
scanned five times while wet.  This same filament was allowed to dry and scanned an 
additional five times on the following day.  The change in SNR with each scan was then 
calculated.  Incubation parameters for these system tests are summarized in Table 4. 
Once basic parameters were established, incubation times were shortened to 
determine the shortest assay time that resulted in positive virus detection.  Virus and 
detecting antibody incubation times were shortened to one minute, and wash times were 
shortened to fifteen seconds.  When this shortened assay time was established, 
experiments were performed to determine the limit of sensitivity of this technique and the 
minimum assay times required to detect lower virus concentrations.  Virus concentration 
was reduced to 3.3 x 109 and 3.3 x 108 for these experiments, and virus incubation time 
was increased until detection was achieved.  A summary of these parameters can be also 
be found in Table 4.  
An important aspect of this optical system is the online detection and control of 
filament positioning. This permits decision on subsequent filament motion for additional 
incubation based on signal strength.  This aspect could be very important for a new 
antibody/antigen pair for which optimal incubation times are not yet known or for rapid 
detection applications in which time is critical.  In this approach a rapid detection 
protocol might be followed to detect a high virus titer and then a negative initial rapid 
screen might be followed up with a high sensitivity but slower detection protocol. A 
single filament was used to show that online detection could be utilized to increase signal 
strength.  In the first experimental design, the filament was repositioned within the 
detecting antibody chamber to increase signal and then scanned again.  In the second 
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experimental test the filament was repositioned within the virus chamber.  In this test the 
first cycle of the experiment used a one minute virus incubation that yielded only a weak 
signal.  Following this initial virus detection measurement, the capture antibody region of 
the filament was sent back to the virus chamber for additional incubation.  After the 
additional virus incubation, processing within chambers 3-5 was repeated.  The filament 
was cycled through this process three times to show the capability of using online 
detection and filament motion to enhance the fluorescence signal.  Table 4 summarizes 
incubation parameters for both repositioning experiments. 
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Table 4:  Incubation parameters for all experiments. 
Experiment Virus Time (min) 
Wash 
(min)
Detecting Ab 
Incubation 
(min) 
Final Wash 
(min) 
Basic Detection 30 3 10 5 
Bleaching Effects 30 3 5 5 
Fast Detection 1 0.25 1 0.25 
Virus Sensitivity 1,10,40 1 5 1 
Detecting Ab Recycling 30 3 0.5, 1, 2 5 
Virus Recycling 1,5,10 1 5 1 
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Results 
As described below, recycling the regions of the filament containing the capture 
antibodies through the reaction chambers and re-positioning within the detector in an 
effort to increase signal was an important aspect of many experiments.  One concern with 
this approach is the bleaching effect of laser illumination on the fluorescence compounds 
and on the antigen-antibody interactions.  Therefore, we first verified that consecutive 
measurements of signal intensity produced similar intensities. Effects of laser 
illumination were investigated by taking multiple scans of two filaments following two 
virus detection experiments.  Each filament was prepared with three anti-M13 regions 
and processed as summarized in Table 4.  Previous observations had shown that 
bleaching may be more problematic for a filament if it remained wet while scanning.  
Therefore, one filament was kept wet during the five scans by cycling the filament back 
to the final wash chamber in between scans and another was allowed to dry before any 
scans were performed.  As Figure 11 illustrates, full power laser illumination did appear 
to consistently decrease the observed signal.  After five successive scans the signal was 
reduced to ~8% of its initial value (left bars of the left panel).  If the filament was 
allowed to dry before measurements were made, the effects were negligible (left bars of 
the right panel).  Allowing the filament to dry would add to the total processing time.  
Since rapid processing was one of the project goals, we first attempted to reduce the laser 
power and determine if this prevented the drop in signal intensity with subsequent scans.  
A polarizer was used to weaken the laser from its full strength of 25 mW to 
approximately 5 mW  
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Figure 11:  Repeated laser scans of virus detection filaments results in a significant signal 
drop for wet filaments using full laser power but not with low laser power (left panel).  
Repeated scans of dry filaments did not show significant signal loss for high or low laser 
power (right panel). 
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In addition,  the filament scanning speed was increased to 4 cm/sec and an 
excitation slit was placed in front of the laser to further reduce laser exposure of the 
filament.  As shown by the right hand bars in the panels of Figure 11, a reduced laser 
power did not change the signal intensity after five successive scans. All subsequent 
results were obtained with these laser power settings. 
Figure 12 shows that regions of the filament containing the capture antibody anti-
M13 produced strong fluorescence signals.  In these experiments each ~3 cm length of 
the filament included one negative control anti-E region and three anti-M13 regions.  
After processing through the five chambers, strong fluorescence signal (SNR 51 ± 4.5) 
was observed in regions of the filament containing immobilized anti-M13 capture 
antibody, indicating successful virus detection  The fluorescence observed in the region 
containing immobilized anti-E capture antibody has fluorescence that is indistinguishable 
from background.  The lack of fluorescence in the anti-E region of the filament indicates 
that, as expected, antigen/antibody binding is a highly specific process and that no virus 
was attached to this region. In this system, higher virus concentrations could be detected 
with shorter virus incubation times. Figure 13 shows the virus incubation time required to 
detect virus of different concentrations along with the SNR achieved in each experiment.  
Detection of 3.3 x 108 virions/ml was achieved in 40 minutes and maintained a SNR of 
over 3.  Raising the virus concentration to 3.3 x 109 virions/ml reduced the required virus 
incubation time to 10 min, while raising the SNR to over 6.  A concentrations of 3.3 x 
1010 virions/mL, the highest concentration tested, reduced the required time even further 
to only 1 minute and maintained a high SNR of almost 10.    
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Figure 12:  Photomultiplier output as a function of filament position. Laser scanning of 
the filament detects virus in all three antibody regions (anti-M13) with a SNR of 
approximately 51 ± 4.5.  Control region (anti-E) is not distinguishable from background. 
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 Figure 13:  Virus incubation times required to detect different virus concentrations.  A 
one minute virus incubation detected 3.3 x 1010 virions/mL with a SNR of nearly 10.  
Concentrations below 3.3 x 108 virions/ml were not detectable with a 75 minute virus 
incubation time.  
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All other reaction parameters remained constant for these experiments (Table 4), so the 
total assay times for these trials ranged from 41.5 minutes for the lowest concentration to 
only 2.5 minutes for the highest concentration.  Since filament blocking can be performed 
ahead of time, blocking times were not included in these estimates. 
 Online detection and control of filament position are unique aspects of FARA.  In 
this approach, a weak signal could potentially be amplified by reprocessing the 
immobilized capture antibody regions through the reaction chambers.  As an initial test of 
this strategy, experiments were performed to test the effects of re-positioning the capture 
antibody region of the filament within the detecting antibody chamber on detecting 
antibody interactions.  The top panel of Figure 14 shows the increase in signal after the 
filament was cycled through the detecting antibody chamber three times for additional 
incubation.  In this assay, signal strength increases by almost a factor of four as the 
filament is re-incubated. 
 Next, a second test of this strategy was performed by repositioning the capture 
regions within the virus chamber for increasing incubation times.  In these experiments, a 
short initial virus incubation time was used for virus detection, so that fluorescence 
intensity was initially low.  After the initial processing was performed and the filament 
scanned, the filament was repositioned within the virus chamber for an additional 
incubation, followed by the standard processing steps in the subsequent chambers.  The 
bottom of Figure 14 shows the increases in signal for cumulative incubation times of 1, 5 
and 10 minutes.   
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 Figure 14:  Signal increases as the capture region of the filament is cycled back to the 
detecting antibody chamber (top) or the virus chamber (bottom) for additional incubation. 
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The filament used for this experiment contained an anti-E negative control region on the 
left of the filament followed by three anti-M13 regions.  Fluorescence increases 
approximately 4-5 fold for the anti-M13 regions from cycle 1 to cycle 3, but there is 
almost no change in the control antibody region. 
 As a final test of the filament repositioning strategy, we compared the signal 
intensities obtained with a single pass through the reaction chambers to the intensities 
obtained with filaments cycled through three successive processing cycles.  As Figure 15 
indicates, the reincubation strategy produced final signal intensities very similar to 
intensities of filaments with continuous incubation times when virus incubation times 
were matched.  This indicates that filament motion and the processing steps does not 
reduce the observed signal.  Furthermore, it suggests that using this system, flexible 
adaptive processing strategies utilizing repositioning of the filament after fluorescence 
measurements can be developed. 
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Figure 15. Comparison of recycling versus continuous virion exposure. Filaments 
repositioned within the virus incubation chamber (black bars) have fluorescence signals 
similar to filament incubated for the same time in one pass. 
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Discussion 
 Previous work on FARA has shown the potential of filament based virus detection 
(43).  High levels of sensitivity and specificity have been shown, along with automated 
processing.  However, automation was limited to filament processing, requiring filaments 
to be removed for fluorescence scanning on a microarray scanner.  The focus of the 
present work is the design and development of a fluorescence-based online detector that 
is integrated with the existing system of microreaction chambers (Figure 9).  Online 
fluorescence detection allows automation of the entire virus detection process with no 
user intervention.  Figure 12 shows typical virus detection results using FARA’s 
integrated optical detection system.  The distinct peaks in the anti-M13 regions signify 
that M13 virus bound to these regions, which subsequently bound a fluorescently labeled 
detecting antibody, which is detected by an integrated detector.  Specificity of virus 
detection is demonstrated by the lack of any detectable peak in the negative control anti-E 
region.  Average SNR for this experiment was over 50, which exceeded any values 
previously reported for FARA, and assay time was shortened by at least 50% of previous 
values. 
 Much of the increase in SNR and decrease in assay time can be attributed to the 
optical flexibility of FARA’s integrated detector.  This detector allows any single filter or 
combination of filters to be used in the emission path.  The ability to customize and 
adjust the emission filters is a major factor in the high SNR.  Previously, detection was 
achieved using a dual laser microarray scanner with set emission filters that were not 
optimal for this application.  Emission bandpass filters for the microarray scanner had a 
very broad bandwidth, so numerous fluorescent dyes could be used.  However, these 
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broad emission filters also passed a significant degree of autofluorescence, which limited 
SNR.  Future designs of FARA’s integrated detector may eliminate most of the specular 
reflectance by mounting the PMTs at a 45° angle from vertical so that the line of 
reflection is not captured. 
 Laser power requirements for filament-based virus detection using FARA were not 
known, so a 25 mW diode laser was a cost efficient way to ensure that ample power was 
available.  It was clear that bleaching of the detecting antibody could be a major issue if a 
filament was to be scanned multiple times.  However, repeated, full power scans of a dry 
filament with multiple regions of immobilized positive control antibodies (AF647 anti-
M13) showed little or no bleaching effects (data not shown).  However, when filaments 
remained wet and underwent repeated scans, it became obvious that the laser at full 
power was having a detrimental effect on either detecting antibody fluorescence or on 
antigen-antibody interactions.  A simple experiment that exposed the filament region of 
interest to laser radiation immediately after the virus incubation made it clear that the 
laser power was great enough to interrupt the bond between the antibody and virus. 
The detection of fluorescence online and the filament movement control give 
FARA the unique advantage of rapid initial virus detection with subsequent high 
sensitivity for virus at low concentrations.  Figure 14 shows how this feature can be used 
to optimize and increase signal.  Fluorescence from the capture regions increases 
significantly after each additional incubation in both the virus chamber and the detecting 
antibody chamber.  A region of interest on the filament can be processed and reprocessed 
until the fluorescence signal reaches a predetermined level.  The virus detection program 
will continue to cycle the filament back through the reaction chambers until the signal 
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reaches this level or until total assay time has reached a preset time.  This could be very 
useful for a different antigen/antibody pair when optimal incubation times are not known.  
On-line fluorescence detection could also be very valuable tool for guiding further 
testing.  Multiple groups of antibody regions, each corresponding to a different test, could 
be immobilized along a long filament.  The results from one group could determine 
which group is tested next.   In this manner, a sample could be probed for many antigens 
in the order which best preserves sample and provides the maximum information about 
the unknown sample. 
Our initial laser detection system appeared to decrease the observable signal 
intensities seen in subsequent readings. Initial experiments utilized the excitation laser at 
its full strength of 25 mW, but qualitative observations indicated that repeated laser 
exposure at this intensity reduced fluorescence not only through bleaching effects, but 
also possibly through an unidentified interruption of the antibody-antigen interaction.  
Experiments exposing the filament to the laser as it exited either the virus chamber or the 
final wash chamber helped distinguish between bleaching effects and the effects on 
antibody-antigen interactions.  In both experimental designs, repeated scans reduced the 
signal intensity.  Exposure of the filament to the laser immediately after the virus 
chamber reduced the SNR by a factor of four, indicating the antibody-antigen interactions 
were being disrupted since no labeled antibody was present at the point in the assay.  
When the filament was exposed to the laser following the final wash, SNR was also 
reduced by approximately a factor of four, indicating that bleaching of the fluorophore is 
occurring.  Based on these observations, we conclude that laser interactions with both the 
fluorophore and the antibody-antigen binding partners contributed to the decline in signal 
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intensity.  Beaching effects are well known, however there appear to be few reports or 
studies directed at the effects of antibody-antigen binding. 
Since laser power appeared to be important, we also estimated the light exposure 
produced under the conditions of these experiments.  The calculated laser exposure for 
each capture region of the filament using full laser power was approximately 1.13 mJ 
during scanning.  This calculation was based on the laser power (25 mW), region width 
(1.5 mm), scan speed (0.5 cm/s), and the width of the filament relative to the laser beam.  
The antigen-antibody interaction is typically made of several non-covalent interactions 
such as hydrogen bonding, dipole-dipole interactions, hydrophobic interactions, Van der 
Waals forces, and sometimes electrostatic interactions.  The strength of the overall 
interaction is a summation of these individual interactions with electrostatic interactions 
and hydrogen bonding being the strongest bonds at 670 kJ/mol and 20 kJ/mol, 
respectively.  The strength of the antibody-antigen bond is strongly dependent on the 
proximity of the contact areas between the antibody paratope and the binding epitope on 
the antigen.  Since every interaction is different, the total energy of such interactions may 
range from the 10’s to 100’s of kJ/mol.  Even if it is assumed that 100% of the antibody 
from the spotting solution adsorbs to the filament and binds virus after the initial washing 
and blocking step, there is still ample laser energy to disrupt all virus-antibody 
interactions if all laser energy were completely absorbed by the surface molecules.  
However, an accurate calculation of this energy is not possible due to two major 
unknowns.  It is unknown how much antibody from the initial spotting solution binds to 
the filament and how much remains active.  In addition, the energy transferred from the 
laser beam to surface antibodies on the filament is also difficult to calculate.  Even 
 78
though the laser exposure is easy to estimate, the amount of adsorbed laser light is still 
unknown.  Most of the absorption of laser light is by the filament itself, so it remains 
unclear how much of this energy is being transferred to the antibodies and antigens on the 
filament.  Since the laser is at a wavelength (638 nm) that is not highly absorbed by 
proteins, the antibodies themselves should not absorb a significant amount of energy.  
Nevertheless, laser exposure at full power was shown to be harmful to virus binding.  
Weakened interactions between virus and antibody allowed the virus to be washed off 
when the capture regions were sent back through the system for additional incubations.  
To limit these effects, a polarizer was placed in front of the laser and adjusted so that the 
laser output was reduced to 5 mW.  To reduce exposure even further, the filament 
scanning speed was increased to 4 cm/sec and an exposure slit was built to reduce the 
area of the filament that was illuminated by fifty percent.  These modifications reduced 
filament exposure by a factor of 100 to approximately 0.014 mJ, and laser effects were 
minimized. 
 
Conclusion 
In summary, the addition of an online optical fluorescence detector increases the 
sensitivity of FARA and provides additional processing flexibility that makes adaptive 
detection feasible. 
 79
CHAPTER V 
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Abstract 
 We have previously described the development of a filament-antibody recognition 
assay (FARA) that creates ELISA-like sandwich structures by positioning a 
monofilament containing regions of immobilized antibodies through a series of reaction 
chambers.  One of these chambers contains the unknown virus solution and when the 
appropriate filament-coupled antibody is present in this chamber, virus is coupled to the 
filament.  Virus detection is achieved by subsequent positioning of the filament within a 
solution of fluorescently labeled detection antibody, and passing the filament through an 
integrated fluorescence detector.  In this report, we describe the application of this 
technology to subtype reovirus.  We have developed a decision tree that tests for virus 
with increasing specificity at each level of the tree.  Using three types of reovirus and one 
bacteriophage, our system correctly detected and identified all three reoviruses at a 
concentration of 2 x 1012 virions/ml and M13K07 phage at 3 x 1011 virions/ml.  
Fluorescence from all peak regions was determined to be significantly higher than 
background regions (p < 0.005).  T3D reovirus diagnosis required three levels of testing 
and resulted in signal to noise ratios (SNR) of 11.5 for general reovirus testing in level 1, 
9.8 for serotype 3 identification in level 2, and 3.3 for final T3D identification in level 
three.  T3SA+ also required three levels of testing before a final diagnosis was returned in 
level 3.  A SNR of 8.8 for general testing, 8.3 for serotype 3 identification, and an 
expectedly low 1.1 for level three testing was found.  T1L was identified in two steps 
with a SNR of 6.4 and 5.1.  M13K07 phage detection only required one step for 
identification and resulted in a very high SNR of 88.  Reovirus provided a simple test 
system to prove the feasibility of a decision scheme that uses online feedback to guide 
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additional testing, but this scheme could easily be expanded into a much more 
complicated system with numerous levels and branches. 
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Introduction 
Although the advancement of modern medicine has led to the eradication of many 
diseases in this country, diagnosis and treatment for the common cold have lagged far 
behind.  The economic impact of this illness to this country is estimated to be in the tens 
of billions of dollars through missed work and low productivity on the job.  When 
caregiver absenteeism is included, this figure jumps into the hundreds of millions of 
dollars (50,51).  Although the development of new antibiotics and anti-viral drugs has 
made significant progress, treatment and diagnosis of the common cold is often 
complicated by the inability to accurately diagnose the etiology behind the illness in a 
clinical setting (52,53). 
In a research laboratory setting, a specific cause of infection can usually be found 
by utilizing a variety of diagnostic tests.  In a majority of patients displaying symptoms 
associated with the common cold, a viral etiology has been shown, with the rhinovirus 
being responsible for 30-50 % of infections.  Coronaviruses, influenza virus, respiratory 
syncytial virus, parainfluenza, adenoviruses, and enteroviruses cause a vast majority of 
the remaining viral infections (51,53-57).  Different pathogens often require different 
techniques for optimal detection, so there is no single method that provides accurate 
diagnosis of every likely pathogen.  Compounding this problem is the fact that each of 
these major pathogens may have numerous subtypes.  Rhinoviruses and influenza each 
have over one hundred different variants, making traditional serological techniques 
difficult and often unreliable (58,59).  However, in a clinical setting, it is often not 
feasible to spend the time and resources to identify a distinct causative agent.  Although 
most studies of the common cold have shown a bacterial etiology in only a small percent 
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of cases, the lack of a definitive viral diagnosis in a clinical setting continues to lead 
many physicians to prescribe antibiotics as treatment for the illness (3,51,60,61).  This 
misuse of antibiotics has led to an increasing number of antibiotic-resistant bacterial 
infections.  
A quick, reliable technique for detecting such a wide range of pathogens does not 
exist.  In the research lab, traditional techniques such as virus isolation, microscopy, and 
serology are used, along with more modern strategies such as direct antigen detection 
(ELISA) and PCR to determine the infectious agent.  A simpler strategy that could 
combine the reliability of traditional techniques with the sensitivity and quickness of 
modern techniques would be very advantageous in a clinical setting.  We have designed a 
system that could eliminate the need for such a wide panel of tests. (43,62).  We have a 
designed a filament based detection strategy where specific antibodies are passively 
immobilized in a linear array along the surface of a monofilament.  The filament is pulled 
through a series of small reaction chambers where the antibodies pull the corresponding 
virus out of solution, if present.  A fluorescently labeled second antibody is then used to 
detect bound virus using a laser excitation source and photomultiplier tube.  The results 
of each test are then fed back to a computer control program, so that the computer can 
decide if further testing is necessary.  Using this scheme, the first set of immobilized 
antibodies corresponds to general virus classes.  If a virus is found, the program moves 
the filament so that the next set of antibodies tested corresponds to one of many subtypes 
of the virus found in test one.  In this manner, each subsequent test becomes more 
specific for a single antigen, and subtypes of viruses not found in the early tests are 
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ignored.  This strategy limits the overall amount of testing as major virus classes are ruled 
out in the early stages.   
We have developed an automated system that uses pre-programmed parameters in 
a knowledge-based decision tree that is increasingly specific in each level (Figure 18).  
We show the effectiveness of our automated system and our decision tree strategy to 
detect the presence of reovirus in solution.  Using a set of reovirus subtypes and one 
bacteriophage, we use a three level decision tree to determine the reovirus subtype.  As a 
human pathogen, reovirus is an excellent test system to show the clinical implications of 
our system, while safety concerns were minimal since reovirus infection in adults is very 
rare. 
 
Methods 
 
FARA: Filament Antibody Recognition Assay 
 A polyester filament (120 µm OD, Sulky Invisible, Punta Gorda, FL) with 
circumferential bands of immobilized antibody was passed through a series of five glass 
micro-reaction chambers that are similar to the five major steps of an ELISA.  Table 5 
gives an overview of the purpose and contents of each chamber.  Antibody regions were 
first rehydrated, and the bare regions of filament were blocked from non-specific binding 
of virus.  Following this step, the immobilized antibody region was incubated in the virus 
chamber for 40 min where virus was captured out of solution if the corresponding 
antibody was present on the filament. Following virus incubation, unbound virus was 
briefly washed away in step 3, before exposure to a fluorescently labeled second antibody 
in step 4.  .The labeled antibody solution in step 4 contained fluorescently labeled 
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antibodies specific to each test virus.  Bound virus from step 2 captured its corresponding 
fluorescent antibodies.  A final wash in the last step removed any unbound reagents, and 
the region of interest was pulled through an integrated fluorescence detector. 
 
Hardware 
Chambers and Stage.  Glass micro-reaction chambers were cut from 1/4-inch 
stock tubing into 75 mm lengths, and the ends were flared outward to facilitate movement 
of the filament through the chambers.  Interior diameters of the chambers were 2 mm or 
0.75 mm (See Table 5) Chambers were arranged linearly on the top of a horizontal 
aluminum stage using machined aluminum mounts.  Linear position of the chambers 
could be finely adjusted due to the oblong mounting holes on each mount.   
Filament Control.  Movement of antibody bands through the chambers was done 
with a rotary stage and control unit from Yaskawa Instruments (Waukegan, IL) and 
controlled by a LabView Virtual Instrument (VI) interface (National Instruments, Austin, 
TX).  The motor wound and unwound the filament around a spindle to move the region 
of interest forward and backwards.  A small weight was placed on the opposite end to 
keep a constant tension on the filament. 
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Table 5:  Purpose and contents of glass reaction chambers. *PBS with 0.1 % Tween 20 as 
a blocking agent 
 
Step Description Solution Incubation Time 
Chamber 
ID 
1 Block/Wash Filament PBS-T* 15 min 2 mm 
2 Virus Incubation Unknown Virus Solution 40 min 0.75 mm 
3 Wash PBS-T 1 min 2 mm 
4 2nd Ab Incubation Flourescently labeled 2nd Antibody 5 min 0.75 mm 
5 Wash PBS-T 1 min 2 mm 
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If extremely long filaments were required, the distal end could be looped back around to 
the spindle using a small pulley so that excess filament could be wound back around the 
spindle as the antibody regions move through the system.  However, following 
fluorescent scanning for most experiments, filament regions were cut and scanned again 
in a GenePix 4000B microarray scanner (Axon Instruments, Union City, CA).  
Parameters such as filament speed and residence times within chambers were all 
controlled through the LabView VI.   
Lasers and PMTs.  The online fluorescence detector was comprised of a central 
sample chamber through which the filament was passed during detection.  Laser 
excitation sources were attached to either side of the chamber as shown Figure 16.  Laser 
1 was a  25 mW, 638 nm diode laser (Coherent, Santa Clara, CA) and was used to excite 
Alexa Fluor 647 fluorescent dye (AF647, Molecular Probes, Eugene, OR).  Laser 2 was a 
532 nm, 20 mW diode-pumped, solid state laser (B&W Tek, Inc., Newark, DE) and was 
used to excite Alexa Fluor 555 dye (AF555, Molecular Probes, Eugene, OR).  Laser one 
was attenuated with a polarizer and an excitation slit, reducing the effective laser power 
to approximately 5 mW.  Laser 2 was not attenuated.   Two Hamamatsu R928 
photomultipliers were attached to the top and bottom of the sample chamber and were 
powered by 850 V and 800 V signals for AF647 and AF555 channels, respectively.  
Current from the PMT was converted to a voltage using transimpedance amplifiers that 
amplified the signal by a factor of 106 for AF647 and 105 for AF555.  Voltage was 
sampled at a rate of 800 samples/sec using a digital acquisition board from National 
Instruments, and signal acquisition was synchronized with filament movement using 
LabView.   
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Filters.  Long pass filters with cutoffs at 685 nm (Chroma, Rockingham, VT) and 
665 nm (Melles Griot, Rochester, NY) were combined to filter out reflected laser light 
from the AF647 channel.  For the AF555 channel, two long pass filters (570 nm cutoff, 
Melles Griot) were stacked with a bandpass filter centered at 565 nm (30 nm bandwidth, 
Chroma) to filter out reflected light.  Filter sets were placed in the light path between the 
sample chamber and the PMTs. 
 
Feedback Control 
Spatially localized fluorescence from the filament was measured as a 0-14 V 
signal from the transimpedance amplifier.  Voltage data from the scan was passed back to 
a peak detection program in LabView that identified all peaks present in the data, the 
location of each peak, and the amplitude of each peak.  Peak detection threshold 
parameters were user defined as 0.3 V (approximately three times background), with a 
width of 30 points.  Although 30 pts represents a width slightly larger than the physical 
tooth width of the comb, antibody spots tended to be drawn out slightly from the edges of 
the tooth.  A width of 30 points minimized the false positives using the peak detection 
program.  Red fingernail polish was used as a visible and fluorescent marker to identify 
spotted regions during experiments and during laser scanning.  The fluorescent fingernail 
polish marks resulted in sharp peaks in all situations.  Since the physical location of the 
immobilized antibody regions in between the markers was known, experiment 
conclusions were based on the distance of the second detected peak from the initial 
fluorescent marker. 
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 Figure 16:  The filament passes through a rectangular sample chamber that has two laser 
excitation sources attached to either side.  Photomultiplier tubes are attached to the top 
and bottom of the chamber.  
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If no peaks were found within the fluorescent markers, the program stopped and indicated 
to the user that no virus was found.  Similarly, if a peak was detected in the negative 
control region of the filament, the program stopped and indicated contamination to the 
user.  If peaks were detected within the region, the program moved the filament 
downstream to the appropriate antibody region for more specific testing.  Downstream 
regions were identified by additional fluorescent markers on the filament.  The VI moved 
the filament forward until the appropriate set of markers was detected, indicating that the 
appropriate antibody region was ready for incubation in chamber 1.  This process was 
repeated at each level of testing.  As an additional check, data obtained with each 
filament scan was loaded into a MATLAB program that allows the user to mark the 
locations of each antibody region.  The program calculates the mean and standard 
deviation of each region selected, and a paired t-test was used to compare capture 
antibody regions with negative control regions.  A p-value less than 0.05 signified 
positive virus detection. 
   
Reagents 
Cells and viruses.  Murine L929 (L) cells were cultured in suspension in Joklik’s 
modified Eagle’s medium supplemented to contain 5% fetal bovine serum, 2 nM L-
glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 g/mL amphotericin-
B.  Reovirus strains T1L and T3D are laboratory stocks.  T3SA+ and T3SA- are 
monoreassortant viruses isolated from L cells that were mixedly infected with T1L and 
either T3C44MA (for T3SA+) or T3C44 (for T3SA-).  T3C44 is a reovirus field isolate 
strain that does not bind sialic acid.  This virus previously was used to infect murine 
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erythroleukemia (MEL) cells, which require sialic acid binding for efficient reovirus 
infection.  T3C44MA was isolated from T3C44-infected MEL cells after several passages 
and is capable of binding sialic acid (63).  T3SA+ and T3SA- contain the S1 gene 
segment, which confers sialic acid binding capacity, from the respective type 3 parental 
strain and all other gene segments are from T1L.  Reovirus purification was performed as 
previously described (63-65).  Briefly, L cells were inoculated with second passage L-cell 
lysate stocks of twice plaque-purified reovirus at a multiplicity of infection of 10 viral 
particles per cell.  Virus was purified from infected cells by freon extraction and CsCl-
gradient centrifugation.  M13K07 purified virus was obtained from the Vanderbilt 
Molecular Recognition Core. 
Antibodies.  Mouse monoclonal reovirus antibodies 4F2, 5C6, and 9BG5 were 
purified from hybridoma supernatants using Protein A column chromatography.  
Reovirus antibody 8H6 was obtained from the Wilson laboratory (Department of 
Pediatric Infectious Disease, Vanderbilt University).  Anti-M13 monoclonal antibody 
was purchased from Amersham Biosciences (Piscataway, NJ). 
4F2 and 8H6 used in Step 4 for fluorescence detection were labeled with AF555 
or AF647, respectively, according to the manufacturer’s instructions.  Labeled antibody 
was purified using PD-10 size exclusion chromatography columns (Amersham 
Biosciences).  The concentration and degree of labeling for labeled antibodies was 
determined using absorbance measurements at 280 nm and at the peak absorbance 
wavelength of each dye.  Aliquots of both labeled and unlabeled antibodies were stored 
long term at –20 °C, while working solutions were kept at 4 °C.  Dilutions of antibodies 
were made immediately prior to experiments.    
 92
Preparation of Immobilized Antibody on Filament 
 Filament regions for immobilizing antibody were placed across the concave teeth  
of a PhastGel sample applicator (Amersham Biosciences) so that antibody spotting could 
be localized to a distinct region (Figure 17).  Surface tension within the teeth of the comb 
kept the antibody from spreading along the filament, allowing for a small distinct spot.  
Antibody was spotted (0.75 µL), and was allowed to passively adsorb to the filament for 
45 minutes in a humidified box.  Following incubation, filaments were rinsed in PBS-T 
and threaded through the reaction chambers for virus detection experiments.  
Experiments were performed to determine the optimal concentration of each antibody.  
Anti-M13, 9BG5, and 5C6 were spotted at concentrations of 0.5, 0.25, and 0.2 mg/mL, 
respectively.  When multiple sets of immobilized antibody was required, multiple sample 
applicators were fastened together and excess filament was wound in between regions to 
assure adequate spacing of the regions.   
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 Figure 17:  Filament is placed within the concave teeth of a PhastGel applicator to keep 
the spotted antibody localized to a small region.   
 94
 Experimental Parameters 
 Virus detection parameters were constant in all experiments.  Incubation times for 
each chamber are summarized in Table 5.  While in each chamber, the region of interest 
was oscillated 2.5 cm at a speed of 1 cm/sec to increase interactions between 
immobilized antibody and virus particles in solution.  PBS-T was used in all wash 
chambers and was used for virus and labeled antibody dilutions.  Concentration of all 
reovirus virus solutions was 2 x 1012 virions/mL.  AF647-8H6, AF555-4F2, and AF647-
anti-M13 detecting antibodies were mixed at a concentration of approximately 40 µg/mL 
for each antibody.  The organization of immobilized antibody bands within each region 
of interest depended on the level of testing.  The region of interest for level one contained 
a PBS negative control spot, followed by a spot of mixed 9BG5 and 5C6 (0.25 mg/mL, 
0.2 mg/mL), and an anti-M13 spot (0.5 mg/mL).  Levels two and three included a 
negative control PBS spot followed by separate 9BG5 and 5C6 spots (0.25 mg/mL, 0.2 
mg/mL).  Solutions were pipetted into appropriate chambers and used for all three levels 
of testing.  If testing proceeded all the way to level three, fluid loss from the chambers 
was monitored and replenished if necessary. 
 
Results 
 The LabView VI coordinated all filament movement, filament scanning, and signal 
feedback into one program.  As described above, this detection system was designed to 
automatically detect the presence of reovirus or M13K07 with increasing specificity as 
testing proceeded from start to finish.  Below is a summary of antibody specificity for 
each test virus:  
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M13K07 →  anti-M13 
T1L →  5C6, 8H6 
T3SA+ →  9BG5, 8H6 
T3D →  9BG5, 8H6, 4F2 
Our LabView program resulted in a theoretical decision tree as depicted in Figure 
18.  If fluorescence was detected from the anti-M13 region of the filament, the program 
returned a diagnosis of M13K07 virus, and no further testing was necessary.  If 
fluorescence was detected in the 9BG5/5C6 region, the program returned a general 
diagnosis of reovirus and advanced the filament to the appropriate region for level 2 
testing, where a more specific test for reovirus was performed.  In level 2 testing, 
fluorescence from the 5C6 region indicated a serotype 1 reovirus, which, in this scheme 
corresponded to T1L reovirus.  A diagnosis of T1L represented an endpoint in the 
decision scheme and testing stopped.  Fluorescence from the 9BG5 region indicated the 
presence of a serotype 3 reovirus, and the program advanced the filament for further 
subtyping in level 3.  Level 3 testing utilized AF555 4F2 antibody as the detecting 
antibody and used a second detection channel with a green excitation laser to differentiate 
between different serotype 3 reoviruses.  If fluorescence was found in the 9BG5 region 
using this channel, a diagnosis of T3D reovirus was returned and testing along that 
branch ended.  When no fluorescence was detected from the second channel for that 
region, the program ended with a diagnosis of T3SA+/T3SA- reovirus.   
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Figure 18:  Testing was divided into three levels of specificity.   The LabView control 
program began at level one and followed different branches of this decision tree based on 
the type of virus found at each level.  When reovirus was detected in level one, filament 
was moved forward to the next antibody region for level 2 testing.   If a serotype 3 
reovirus was found (T3D, SA+, SA+) in level 2, testing continued for one more level to 
distinguish between these types.  Negative control PBS spots were included in each 
testing region.  Fluorescence detected in these negative control regions indicated 
contamination, and the program returned an error message.  
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Fluorescence detected in the negative control PBS regions of any level indicated 
contamination, and the program stopped and returned an error message to the user.  This 
situation did not arise during testing.  
Figure 19 illustrates the specificity of each test antibody towards its 
corresponding virus.  Results shown correspond to each level of the decision tree that 
pertained to each of the four test viruses and show fluorescence (as voltage) as a function 
of filament position for separate filaments.  After each experiment, filaments were also 
scanned in a microarray scanner, and the resulting images are included at the top of each 
panel.  The top panel shows a distinct peak for each curve in the 9BG5 antibody region, 
indicating successful detection of T3D.  The red curve corresponds to level 1 and level 2 
testing that used AF647-8H6 as the detecting antibody, while the green curve 
corresponds to level 3 testing that used AF555-4F2 and the second detecting channel.  
Neither curve shows cross reactivity of T3D reovirus with the immobilized 5C6 region or 
negative control PBS region. 
The second panel of Figure 19 shows the equivalent data set using the T3SA+ 
reovirus where the red curve corresponds to level 1 and level 2 testing, and the green 
curve corresponds to level three testing.  As expected, fluorescence is detected from the 
9BG5 region using AF647-8H6 detecting antibody (red curve) but not when using 
AF555-4F2 antibody and the second detecting channel as is done in level 3 testing (green 
curve).  No detectable cross reactivity is found in the 5C6 antibody region or negative 
control region.   
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Figure 19:  Immobilized antibody on the filament detects reovirus and M13K07 phage 
using AF647-8H6 (red) or AF555-4F2 (green).  Top two panels also show specificity of 
AF555-4F2 for T3D over SA+ corresponding to level 3 testing.  Line graphs represent 
data from online detection.  Images were obtained using a dual laser flatbed microarray 
scanner. 
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Detection results for T1L virus are shown in the third panel of Figure 19.  Only 
one curve is shown, corresponding to level 1 and level 2 testing since T1L testing does 
not continue in level 3.  The expected fluorescence is detected in the 5C6 antibody 
region, and no distinguishable fluorescence is seen in the 9BG5 or PBS regions.  The 
bottom panel of Figure 19 shows results using M13K07 analogous to level 1 testing.  
Strong fluorescence is seen in the anti-M13 region but not in the 9BG5/5C6 or PBS 
regions, which was expected.  The four panels of Figure 19 represent each level of 
detection of the decision structure shown in Figure 18, and no detectable cross reactivity 
was seen at any of the three levels.   
The LabView decision making process is based on the presence or absence of 
fluorescence peaks at known locations along the filament, so peak height is not taken into 
consideration when making the diagnosis.  Table 6 shows results from multilevel, 
automated detection of each virus.  The left side shows the layout of antibody regions for 
each level.  The table on the right shows the location of peaks detected at each level of 
the automated experiments and the corresponding LabView diagnosis.  For all multi-step 
experiments, LabView diagnosed the virus with greater specificity at each level.  For 
each reovirus tested, level 1 resulted in a general identification of reovirus, so testing 
continued in level 2 where diagnosis became more specific and differentiated between 
serotype 1 (T1L) and serotype 3 (T3SA+, T3SA-, and T3D) reovirus.  For T1L, testing 
stopped here after a positive result, but for serotype 3 viruses, testing continued one step 
further.   
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 Table 6:  Automated virus detection and diagnosis for each test virus.  The figure on the 
left shows the layout of immobilized antibody regions for each level.  The table on the 
right side shows the location of peaks found by LabView during automated, multilevel 
detection, along with the corresponding LabView diagnosis.  For each virus, diagnosis 
gets more specific with each level of testing. 
Virus Level Peak Position 
LabView 
Diagnosis 
1 9BG5/5C6 Reovirus 
2 9BG5 Type 3 Reovirus T3D 
3 9BG5 T3D 
1 9BG5/5C6 Reovirus 
2 9BG5 Type 3 Reovirus T3SA+ 
3 None T3SA+ 
1 9BG5/5C6 Reovirus T1L 
2 5C6 T1L Reovirus  
M13K07 1 Anti-M13 M13K07 
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Step three diagnosis depended on the presence of a peak in the 9BG5 region for a positive 
T3D result and the absence of a peak for a SA+ or SA- positive result.  M13K07 
diagnosis was made in one step, so no further testing was necessary. 
Since LabView Diagnosis was based only on the presence or absence of 
fluorescence peaks, an independent statistical analysis was made using MATLAB to 
make sure each peak found was statistically significant when compared to background 
values.  The MATLAB program calculated the average and standard deviation of each 
antibody region so that SNR could be calculated and a statistical analysis could be made.  
Table 7 summarizes the peak heights and standard deviation obtained with MATLAB.   
Statistical analysis shows that signal from each peak region is statistically greater than 
background (p < 0.005).  It should be noted that the 9BG5 antibody region for level 3 
testing of T3SA+ shows a statistically significant signal increase over the negative 
control region using this MATLAB analysis.  However, this is merely a result of slight 
fluctuations in the background signal along the filament length, including a slight dip of 
the signal in the negative control region.  A close inspection of the data set show that the 
apparent peak is merely an artifact which is suggested by the low calculated SNR of 1.1.   
No peak was found using the LabView detection program for this region.  
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Table 7:  Average and standard deviation of peak heights determined by MATLAB.  
SNR was calculated by dividing average peak voltage by the average negative control 
voltage.  All peaks were shown to be statistically significant with p < 0.005.  *The peak 
corresponding to level three detection of T3SA+ was not found by LabView, but noise 
present in the background signal was great enough to create a false positive during 
MATLAB analysis.   
 
Virus Level Peak Height (voltage) SNR 
Statistically 
Significant? 
1 0.78 ± 0.071 11.5 Yes 
2 1.1 ± 0.12 9.8 Yes T3D 
3 0.47 ± 0.057 3.3 Yes 
1 1.17 ± 0.12 8.8 Yes 
2 0.35 ± 0.081 8.3 Yes T3SA+ 
3 0.052 ± 0.006 1.1 Yes* 
1 0.344 ±  0.062 6.4 Yes T1L 
2 0.39 ± 0.048 5.1 Yes 
M13K07 1 6.44 ± 1.03 88 Yes 
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Discussion 
FARA was first reported using immobilized anti-M13 antibody regions to detect 
the presence of M13K07 phage (43).  This virus and antibody pair provided a well-
characterized test system to show the feasibility of a filament-based virus detection 
platform; however, filaments needed to be removed from the system for fluorescence 
scanning.  Further improvements were made to FARA that included an integrated 
fluorescence detector, so filaments could be immediately scanned for fluorescence, and 
results could be passed back to the filament control program (62).  The integrated 
detector allowed for adaptive virus detection where regions of interest along the filament 
could be re-incubated in the appropriate reaction chambers to increase filament 
fluorescence when the initial signal was too low. 
In this report, we utilize the unique feedback capability to guide additional testing 
based on the current results.  Following the five-step incubation in the reaction chambers, 
the LabView VI immediately scans the region of interest for fluorescence.  This data is 
then used to make a diagnosis based on the known locations of immobilized antibody 
regions.  Figure 18 summarizes the theoretical decision tree resulting from the VI 
programming.  Using online fluorescence detection and signal feedback, we were able to 
progressively diagnose the presence of reovirus with greater specificity at each level of 
testing (Table 6).   
FARA relies on the ability of passively adsorbed antibodies on the surface of a 
monofilament to capture virus from solution.  The use of a fluorescently labeled detection 
antibody that recognizes bound virus results in localized fluorescence from that region. 
The ability of bound antibody to retain its functionality is critical to the success of this 
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system.  Each of our immobilized test antibodies retained their functionality and could 
detect a reovirus concentration of 2 x 1012 virions/ml as shown in Figure 19.  Distinct 
peaks are present for each immobilized antibody region when incubated with its 
corresponding virus.  The absence of peaks in the negative control regions and in non-
specific antibody regions shows that cross reactivity is not a problem for this system. 
It is clear from Figure 19 that detection of reovirus is possible using FARA, but 
our filament control program in LabView must automatically find each peak, calculate its 
location along the filament, and make a decision regarding additional tests based on the 
diagnosis.  The LabView peak detector VI uses an algorithm that fits a quadratic 
polynomial to sequential sets of points, depending on the width parameter entered by the 
user.  The data is then compared to the threshold parameter, also entered by the user, to 
determine peaks.  Our LabView VI then makes a binary decision to stop or continue 
testing based on the location and number of peaks found.  For each virus tested, LabView 
found the appropriate peaks, returned the appropriate diagnosis, and continued testing 
when necessary.  Table 6 summarizes the results from these automated experiments using 
each of the four test viruses.  For multilevel experiments (T3D, SA+, T1L), results in 
Table 6 represent single filaments with multiple test regions. 
To ensure that LabView peak detection represented peak values that were 
statistically significant over background, data curves were analyzed externally using 
MATLAB.  The mean and standard deviation from peak regions and negative control 
regions were compared to calculate SNR and statistical significance.  In all cases where 
LabView found peaks, SNR was calculated to be greater than three, and fluorescence 
differences between peak and negative control regions were all statistically significant (p 
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< 0.005) as shown in Table 7.  However, this table shows a statistically significant peak 
not found by LabView in the 9BG5 region of T3SA+ level 3 testing.  Level 3 testing uses 
AF555-4F2 as the detecting antibody, so no peak should be present using this virus.    
Although SNR is only 1.1, the resulting p-value is less than 0.005.  Close inspection of 
the data show that this is merely an artifact of fluctuating background noise, including a 
slight dip the background in the negative control region.  MATLAB analysis of the data 
proves that LabView has not produced any false positives and all peaks represent 
statistically significant increases in signal over background. 
Accurate positioning of the filament is another major issue of multilevel testing.  
For level one testing, the first test region can be positioned manually before the 
experiment begins.  However, for subsequent testing, the VI needs to keep track of 
filament position so it knows when the second testing region is located in chamber 1.  
This was achieved with a very simple bar code system using the same fluorescent 
markers used to identify each region of interest.  After a region is scanned, the program 
moves the filament forward until a known pattern of fluorescent markers is detected, 
indicating that the next region is located in chamber 1 for testing.  Since our system only 
involved three levels, the program searched for one or two marks corresponding to levels 
two and three, respectively.  However, it would be easy to incorporate more complex bar 
codes using additional spots or patterns of spots for more complicated systems.  
Reovirus is typically used to study the mechanisms of viral infections and viral 
pathogenesis in mice.  Although it is a human pathogen, it is rarely associated with adult 
human disease(28,30,31).  Many reovirus field isolates have been very well characterized 
and a broad array of antibodies are available that recognize reovirus with varying 
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specificity, which is a requirement of our approach (66).  For these reasons, reovirus was 
a suitable test system to show clinical relevance to this system, while alleviating some 
safety concerns in the laboratory.  However, we observed an interesting phenomenon 
while testing the reovirus antibodies.  Not every antibody was suitable for use as an 
immobilized primary antibody.  Neither 8H6 or 4F2 antibody yielded positive results 
when used as the primary antibody, even if virus incubation time was dramatically 
increased (results not shown).  It is possible that these antibodies undergo more extreme 
conformational changes than other antibodies when passively adsorbed to a solid 
substrate, rendering them inactive.  However, a more likely cause is the location of the 
proteins they recognize on the reovirus surface (28,66).  8H6 and 4F2 recognize the µ1c 
and σ3 proteins from the outer capsid surface of the virion.  Each virion contains 
approximately 600 copies of each protein on the surface of the viral core, but their are λ2 
proteins arranged as pentamers extending outward from the surface of the core with 
oligomers of the σ1 protein extending even further.  It is possible that these extensions 
from the virion core are sterically hindering the surface µ1c and σ3 proteins from getting 
close enough to the filament surface to bind to the 8H6 and 4F2 antibodies.  The same 
reasoning could explain why 9BG5 and 5C6 were both excellent primary antibodies since 
they recognize the σ1 protein that extends furthest from the viral core.  The inability of 
8H6 and 5C6 antibodies to be effective primary antibodies complicated our virus 
detection scheme.  Since 8H6 is non-serotype specific and should bind all reovirus, we 
had to find an alternative immobilized antibody for level 1 testing.  5C6 and 9BG5 
antibodies are serotype specific for type 1 and type 3, respectively, so immobilizing a 
mixture of these was effective for general reovirus detection in level 1.  Although 4F2 is 
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typically specific for all type 3 reovirus, T3SA+ is a reassortant mixture of type 1 and 
type 3 reovirus that contains the σ3 gene segment from type 1.  As a result, 4F2 did not 
recognize T3SA+ and was specific only for T3D in our scheme.  Since 4F2 could not be 
used as a primary antibody in level 3, we incorporated a fluorescently labeled 4F2 
antibody as the detecting antibody and used a separate channel for detection.  When these 
antibodies are in solution trying to bind to an already bound virus, steric hindrance is no 
longer an issue. 
 
Conclusion 
We have shown the feasibility of a programmable, completely automated system 
for diagnosing specific reovirus subtypes.  Although the scheme we report is a relatively 
simple example of this, a much more complicated design could be easily envisioned.  
Each region used for testing could contain many more antibody regions that currently 
used, and there is effectively no limit to the overall length of the filament that could be 
used, so dozens of testing regions could be incorporated into one long filament.  The 
most important requirement is the availability of a full panel of antibodies with a wide 
range of specificity.  Many of the issues concerning primary antibodies and steric 
hindrance could be surpassed by alternative linking strategies to the filament.  Using a 
flexible linker such as poly-l-lysine or other polymer would confer some freedom of 
movement for immobilized antibodies, negating the effects of steric hindrance for bulky 
viruses.   
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE WORK 
 
Potential Applications 
 As mentioned previously, this technology could be very useful for probing a 
biological sample for numerous viruses in clinical setting.  However, one could easily 
envision use of this technology in the area of biodefense.  The ability of the filament to 
probe huge volumes could make it a good candidate for detecting airborne pathogens.  
The filament could be woven into a mesh-like configuration to increase surface area 
exposed to air.  Following exposure, the mesh could be unraveled and sent through the 
system of reaction chambers for processing.  Although airborne pathogens would 
probably be present in extremely low concentrations, huge volumes of air could be 
collected with a vacuum system and passed over the mesh of antibody probes serving as a 
course filter.  In this way, very low concentrations of airborne pathogens could be 
detected.  Probes representing many common biological threats could be immobilized on 
the mesh framework to create a “universal” biowarfare detection kit that is only limited 
by the availability of effective antibodies to each threats. 
 This technology could also be useful for environmental monitoring.  Similar to the 
biowarfare detection kit, probes specific for common pollutants could be immobilized on 
the filament.  The filament could then be dragged through a reservoir and processed to 
monitor levels of various pollutants.  Again, the ability to probe large volumes will help 
detect molecules of interest that may be present only in low concentrations.  Monitoring 
byproducts and or pollution in pipe flow would also be a very attractive application for 
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the system.  Running the filament through the pipe and positioning the probe of interest 
in the middle of the flow could allow monitoring of numerous compounds.  Probes could 
be processed and reprocessed at set time intervals until the signal of interest reaches a set 
level.  Possible applications for this system are countless, but an ideal application would 
be able to take advantage of every unique property of this system, including the 
flexibility, sensitivity, and efficiency, and would be able to take advantage of the 
feedback system.  
 
Future Work 
 Many areas of this technology remain to be fully explored.  The sensitivity of this 
system is something that can always be improved further.  Different primary antibody 
immobilization techniques could prevent much of the antibody functionality loss that 
results from passive adsorption to a solid substrate.  Site-specific attachment of the 
antibody to the filament would greatly increase antibody functionality by leaving the 
binding sites free for antigen binding, and flexible linker arms could eliminate the effect 
of steric hindrance that was problematic for some antigen/antibody combinations. 
 Other detection strategies could also benefit our detection platform.  The use of 
quantum dots, for example, could increase fluorescence due to their high quantum yield.  
In addition, the resistance to bleaching, the wide array of colors that are available, and the 
ability to excite them all using a single excitation source might make them an attraction 
detecting molecule over fluorescent dyes.  Multiple detection channels could be 
incorporated simply by integrating an emission filter wheel in between the sample 
chamber and photomultiplier. 
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 Alternative designs for the glass sample chambers could also greatly improve the 
functionality of the system.  Incorporating some fluidics into the chambers would allow 
easy flushing of chambers in between experiments, so fluid loss from chambers would no 
longer be a problem.  Detecting molecules could be introduced to the chambers before 
each experiment rather than in a mixture at the beginning of testing. 
 Incorporating DNA into this detection system represents a major avenue of research 
that has not yet begun.  Although linking strategies and incubation steps may differ for 
DNA detection, most of the principles and core components of the system could remain 
the same.  DNA detection would show an even greater level of flexibility of this assay 
and would open up even more applications for this platform.  
 There are many possible avenues to explore that could improve this technology or 
expand the potential applications of this technology, but it is not feasible to list them all 
here.  However, the previous work on this system has provided a solid base from which 
to launch new areas of research and development. 
 111
APPENDIX A 
 
MONOFILAMENT PROPERTIES AND SELECTION 
 
Table 8:  Physical and chemical characteristics of some potential filaments.  Of these, the 
Sulky Invisible and Text-Dev PP were chosen initially for their combination of minimal 
autofluorescence, excellent flexibility, chemical compatibility, and size. 
Autofluorescence 
Filament Composition Diameter (µm) Cy3 Cy5 Fluorescein Rhodamine 
Flexible Organic compatibility 
Spiderline 
super mono Polyethylene? 270 N N N N Y Y 
Glass Fiber 
Optic Glass 400 N N N N N Y 
Stren PVDF 410 N N Y N Y Y 
Ande#6 Nylon mix 180 Y N N N Y Y 
Dupont 
0.012 Nylon 300 Y N N N Y Y 
Silk thread Silk 170 N N N N Y Y 
Wonder 
Invisible Nylon 90 Y N N N Y Y 
Sulky 
Invisible Polyester 120 N N N N Y Y 
Text-Dev 
PP Polypropylene 180 N N N N Y Y 
 
Four key characteristics of the ideal monofilament were identified and were used 
to evaluate nine commercially available filaments.  The four main criteria included 
diameter, autofluorescence using four different filter cubes, flexibility, and organic 
solvent compatibility.  Common filaments are made of various materials such as 
polyethylene, polyester, nylon, glass, PVDF, and silk.  Probe immobilization has not been 
extensively studied on any material other than polystyrene and glass, so the composition 
of potential filaments was not a factor other than the way in which it affected our four 
criteria.  In addition, all of these materials (except silk thread) exhibited adequate strength 
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and abrasion resistance, so this was also not a factor in choosing the filament other than 
eliminating silk thread as an option.  The results are summarized in Table 8. 
Autofluorescence was determined by taping each filament to a glass slide and 
imaging them under an inverted fluorescence microscope using filter sets corresponding 
to Cy3, Cy5, fluorescein, and rhodamine.  Any filament that showed significant 
fluorescence using any one of these filter sets was immediately discarded.  The flexibility 
required is only enough to wrap around a 3/4” spool attached to the prototype motor 
shaft.  All of the polymer filaments easily met this requirement, but the glass optical fiber 
became much too brittle after the protective plastic cladding was removed.  Organic 
compatibility was estimated by soaking the filaments in various organic solvents that 
could potentially be used as liquid valves for our chambers.  Liquid valves are organic 
liquids that may be used to seal the ends of the reaction chambers to prevent fluid loss 
and will be discussed later.   All of the filaments appeared to have adequate solvent 
compatibility. 
For the three remaining possible filaments under 200 µm (Wonder Invisible, 
Sulky Invisible, Text-Dev PP), autofluorescence was tested again using our GenePix 
4000B microarray scanner to increase sensitivity of the test.  This testing revealed that 
the Wonder Invisible nylon filament displayed 2-3 times the autofluorescence in the Cy3 
channel than the Sulky Invisible filament, which had 2-3 times the autofluorescence of 
the polypropylene, making the polypropylene the best initial choice. 
 One filament characteristic that merits further discussion is that of filament diameter.  
The optimal filament diameter is partly influenced by the diameter of our reaction 
chambers.  Since a major benefit of the system is greatly reduced diffusion distance for 
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target molecules, an ideal filament diameter should be very close to the chamber diameter 
to minimize this distance.  Therefore, from this standpoint, available filament and 
chamber diameters will determine the sizes of each that are chosen.  However, filament 
diameter also may have an effect on assay sensitivity independent of chamber size.  This 
system immobilizes probe around the entire circumference of the filament and, 
theoretically, will bind virus and detecting antibody around the entire circumference, as 
well.  However, since our excitation light source shines only on one side of the filament, 
it is not clear how much signal is detectable from the opposite side.  The absorbtivity of 
the fiber is still unknown to us.  Attempts thus far to measure this property on a UV/VIS 
spectrophotometer have been unsuccessful.  If absorption is significant, then the filament 
diameter obviously plays an important role in determining how much excitation light will 
reach the opposite side of the filament.  The current filament of choice is transparent, so 
we do not believe that absorption of visible excitation light is a major problem. 
 As stated above, the polypropylene filament fulfilled many of the identified 
requirements for this system, however a major question remained concerning the ability 
of polypropylene to passively bind protein.  Therefore, both polypropylene and polyester 
filaments were used for testing.  Although both polypropylene and polyester filaments 
were both found to adequately bind antibodies, the polypropylene filament often resulted 
in less defined, splotchy filament fluorescence during virus detection experiments. 
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APPENDIX B 
 
CHAMBER DESIGN AND FLUID LOSS 
 
Chamber design was critical for optimizing the signal and maintaining consistent 
results within runs and between runs.  We identified three important parameters involved 
with this part of our experimental design.  First, the size of the chamber should minimize 
reaction volumes and diffusion distance for target molecules, so that the time required for 
maximum probe/target interaction is short.  Next, the chamber should be designed to 
minimize fluid loss to the environment.  Third, it should be made out of a material that 
will not react with or hinder binding between probes and targets and should also allow 
monitoring of fluid levels within. 
For the preliminary studies, chambers were made from 700 µm ID, 25 µl capillary 
tubes to avoid difficulties of working with very small tubes.  Even with this relatively 
large capillary tubing, diffusion distance for target molecules is still very small compared 
to most array techniques.  The maximum radial diffusion from the filament to the wall of 
the capillary is only 290 µm, compared to over 1 cm for most array techniques; however, 
the time scale for diffusion of this distance is still much too large.  Assuming diffusion 
constants of 1x10-7 and 1x10-6 (20-22), a simple calculation predicts approximately 2 hrs 
and 0.2 hrs, respectively, to achieve that distance.  Significantly smaller capillary tubing 
is available, but durability for these small capillaries is a major problem.  To improve the 
durability of reaction chambers, we used 1/4” stock glass tubing that is availability in 
several different inner diameters and cut it into 75mm lengths.  This tubing improved the 
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strength of these chambers, and made filling, emptying, and washing of the chambers 
much easier.  Much smaller inner diameter tubing is available that would reduce the 
diffusion distance even further and reduce the required filling volume to only a few 
microliters. 
  Initial experiments were performed with open-ended capillaries; however, fluid loss 
to the environment was a potential problem with this design.  Evaporation from the 
capillaries was limited to approximately 5% from each end during a two hour mock 
experiment when the filament was not pulled through the interior, but passage of the 
filament through the lumen caused fluid loss to approach 15% from each end, which is a 
significant problem.  The use of organic liquid valves initially appeared to be a relatively 
simple solution that we explored.  A very small volume of an organic liquid placed at the 
ends of the reaction chambers could prevent fluid loss when the liquid is one that has 
very low vapor pressure and high surface tension.  The former will inhibit evaporation 
while the latter will keep the valve in place and prevent reaction fluids from 
contaminating adjacent chambers as the filament is pulled through.  Figure 21 displays 
surface tension and vapor pressure values for numerous common organic solvents.  
Propyl benzoate was initially chosen due to its high surface tension and low vapor 
pressure, but initial attempts at integrating this compound as a liquid valve were not 
successful.  It has been suggested that antibody tertiary structure is disrupted at the 
organic/aqueous interface (67), which may prevent binding of probes to targets.  We have 
identified some other candidates that may be effective as liquid valves such as mineral oil 
and glycerol that are known to be biocompatible with proteins and should not disrupt 
protein folding.  These experiments have not yet been performed. 
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  A second solution involved placing short lengths of heat-shrink tubing on the ends of 
each capillary.  Although the final size of the heat-shrink tubing was only slightly smaller 
the capillaries, it reduced fluid loss significantly.  In fact, fluid loss using this solution 
was diminished to the point where it is approximately equaled the static system with no 
filament movement.  As we incorporated the larger OD tubing, it was no longer feasible 
to use heat-shrink tubing to minimize fluid loss.  We initially designed some chambers 
with a narrow neck at each end that should have the equivalent effect of the heat shrink 
tubing.  However, the narrow neck negatively affected virus detection, probably though 
increased shear stress as the filament passed through the chambers.  Our final design 
eliminated the narrow neck in favor of an outward flare at each end.  The flared end 
appeared to help minimize fluid loss through capillary effects, indicating that much of the 
fluid loss was caused by the filament “pulling” solution from the chambers.  
 
 
Figure 20:  Four chamber designs used for virus detection.  Liquid 
valves are depicted in the top design followed by the heat shrink 
tubing design, narrow-necked chambers, and simple flared 
chambers at the bottom. 
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Figure 21:  Surface tension and vapor pressure values for many common organic 
solvents.  Propyl benzoate (#39) was initially chosen as a liquid valve due to its high 
relative surface tension, low vapor pressure, and availability. 
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APPENDIX C 
 
EFFECT OF SHEAR STRESS ON VIRUS DETECTION 
  
Table 9:  Shear stress calculations using a four different chamber sizes and three different 
filament speeds.   
Shear Stress (Pa) 
Chamber 
Diameter (µm) 
Wall to filament 
Dist (m) 2 cm/sec 1 cm/sec 0.5 cm/sec 
200 4.00E-05 0.500 0.250 0.125 
300 9.00E-05 0.222 0.111 0.056 
750 3.15E-04 0.063 0.032 0.016 
1000 4.40E-04 0.046 0.023 0.011 
 
Shear stress = (dynamic viscosity x filament velocity) / distance to wall 
Dynamic viscosity = 1 x 10-3 Ns/m2 (same as water) 
Filament diameter = 120 µm 
 
 
 Since shear stress created by filament movement may reduce virus binding, an 
estimation of shear stress was made based on filament movement parameters within the 
capillary chambers.  Shear stress is equal to the product of dynamic viscosity and 
filament velocity divided by distance between filament and capillary wall (68).  
Assuming a dynamic viscosity equal to water at 20°C (1x10-3 N.s/m2), shear stress 
resulting from moving the filament 1 cm/sec in a 750 µm chamber is approximately 0.3 
dynes/cm2 (0.03 Pa).  This low level of shear stress should not significantly affect 
antigen/antibody interactions.  This calculation is based on perfect concentricity of the 
filament within the chamber, so the actual shear may vary from that value, depending on 
the position of the filament.  However, even if misalignment of the filament reduces the 
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distance between the filament and wall by a factor of 100, the shear stress is still 
relatively low.  Many reports in the literature show reduced antigen binding as a result of 
shear stress, but most of these studies use shear stress that are several orders of magnitude 
greater than what is present in this FARA system (69).  It does not appear that any further 
reductions in chamber size or misalignment of the filament will create a high enough 
shear stress to have a negative effect on virus detection using our current filament 
movement parameters. 
We tested glass chambers with a narrow neck at each end of approximately 200 
µm that were designed to minimize fluid loss.  Several of these experiments used a global 
filament movement speed of 2 cm/s.  Qualitative analysis of these experiments showed 
that the combination of a very small neck and higher filament speed had a negative 
impact on virus detection.  All subsequent experiments used flared chambers rather than 
necked and filament speed was limited to 1 cm/s. 
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APPENDIX D 
 
LIGHT ACTIVATED ANTIBODY COUPLING 
 
The theory behind the following experiments is explained by Holden and Cremer 
in “Light Activated Patterning of Dye-Labeled Molecules on Surfaces” (70).  The first 
experiment shows that FITC labeled anti-M13 can be attached to the polyester filament 
using the UV gel box.  In that experiment, the entire filament was incubated with FITC 
labeled anti-M13, but only the three green regions were exposed to UV light.  The 
antibody was successfully immobilized only in the three exposed areas.  There is a lot of 
remaining green fluorescence showing that the FITC was not completely bleached (top 
panel of Figure 22).  The subsequent virus detection experiment using this filament did 
not work as shown in the lower panel of Figure 22 where red fluorescence is not seen.  
See GS Lab Book #6, 8-3-05, p. 51 for details of this experiment.  
 
 
Figure 22:  Filament fluorescence after using gel box to bleach FITC labeled antibody onto 
the filament.  Green fluorescence shows that FITC anti-M13 is attached to the filament but 
did not get completely bleached.  This filament was used in a virus detection experiment, but 
did not successfully detect virus as shown by the lack of red fluorescence in the bottom 
picture. 
  
The second experiment described here contained three sets of three antibody spots 
followed by a negative control (Figure 22).  The first set contained three FITC anti-M13 
regions that were bleached onto passively adsorbed fibronectin.  The second set was 
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FITC bleached directly onto the filament.  The third set was the typical passive 
adsorbtion used in most experiments, and the final spot is a negative control anti-E spot.  
Average spot fluorescence from each set was similar, but the passively adsorbed set 
appeared less defined than the bleached regions.  This observation was seen in several 
experiments comparing passive adsorption to bleaching.  See Kelvin Lab Book #1, p. 85 
for details of this experiment along with fluorescence values.  For additional bleaching 
experiments, see Kelvin Lab Book #1, p. 83-86, 92-93.  More testing is necessary to 
determine the value in bleaching antibody regions on the filament, but it appears to create 
more defined antibody regions. 
 
 
Figure 23:  Virus Detection results using bleached filament.  Passively adsorbed anti-M13 
regions appeared less defined than bleached regions.  The presence of fibronectin in 
bleached regions did not appear to have an effect.  Average fluorescence intensity from 
the three different treatments was similar.   
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APPENDIX E 
 
GOLD FILAMENTS 
 
 The following experiments show the potential gold as a substrate for virus detection 
experiments.  The true value of using a gold substrate is the easy covalent coupling of 
antibodies to gold using cysteine residues on the antibody.  However, our experiments 
started only with passive adsorption to gold.  The first experiment utilized a gold wire 
with five passively immobilized anti-M13 regions.  The wire was then incubated offline 
in test tubes for each step and scanned on the microarray scanner.  Figure 24 shows 
successful virus detection in all five antibody regions.  See GS Lab book #5, 7-12-05, p. 
41 for details on this experiment 
 
 
Figure 24:  Gold wire showing virus detection using five regions of passively 
immobilized anti-M13 regions. 
 
 A major advantage of gold substrates is its electrical conductivity.  This conductivity 
can be taken advantage of by applying a potential to the wire to attract oppositely charged 
antigens in solution to speed up antigen movement towards the surface of the wire.  
Using gel running buffer, we applied a either a positive or negative potential to the 
filament and compared virus detection results.  All steps other than the virus incubation 
step were done offline in test tubes.  The positive voltage should attract virus particles in 
a 1x gel running buffer, while a negative voltage should repel them.    Figure 25 shows 
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that a positive voltage results in an increase in fluorescence of approximately 30x over 
negative voltage.  See GS Lab Book #5, 7-21-05, p. 57 for details of this experiment. 
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Figure 25:  Virus detection using a gold wire with applied positive and 
negative voltages.  Positive voltage on the wire increase fluorescence by a 
factor of approximately 30. 
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APPENDIX F 
 
MATLAB CODE FOR AIM III 
 
This MATLAB script was used in Aim III to find the average and standard 
deviation of the raw fluorescence data obtained through LabView.  This code was written 
by Rob Brychta. 
 
%greg_peak_detect2 
 
close all, clear all, clc 
%Choose a File 
[filename, pathname, filterindex] = uigetfile( ... 
       {'*.xls','Excel File (*.xls)'; 
       '*.txt','Text Files (*.txt)';... 
        '*.*',  'All Files (*.*)'}, ... 
        'Pick a file', 'Untitled.xls'); 
if (filterindex > 0) 
    if (filterindex==1) 
        cd(pathname); 
        [numeric,txt,raw]=xlsread(filename); 
        %cols = txt(2,:);  %This is where the column headings are (row number 2 for now) 
        cols = txt(1,:); 
        for i = 1:length(cols) 
            id1(i) = strncmp('y',lower(cols(24)),1); 
        end 
        id1 = find(id1); 
        numcols = length(id1); 
        y = numeric(:,id1); 
     
    elseif (filterindex == 2) 
        cd(pathname) 
        [header,tags,data] = read_txt_greg(filename,pathname); 
        for i = 1:size(tags,1) 
            id1(i) = strncmp('y',lower(tags(i,:)),1); 
        end 
        id1 = find(id1); 
        numcols = length(id1); 
        y = data(:,id1); 
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        y = cell2mat(y); 
        y = str2num(y); 
    end 
     
    for i = 1:numcols 
        ynew = y(:,i); 
        nanid = isnan(ynew); 
        nanid = find(nanid); 
        ynew(nanid) = []; 
        figure, 
        plot(ynew) 
        axis tight 
 
        button = 1; 
        ii = 1; 
        while(button ~=3); 
            waitfor(gcf,'CurrentCharacter',double('d')); %to zoom 
            %select center of cell 
            [xcoordt, ycoordt,button] = ginput(1); 
            if (button == 3),  
                break, 
            else 
                xcoord(ii) = round(xcoordt); 
                ycoord(ii) = ynew(xcoord(ii)); 
                hold on, plot(xcoord(ii),ynew(xcoord(ii)),'r+') 
                ii = ii+1; 
            end 
        end 
        win = [-7:7]; 
        xmat = repmat(xcoord(:),1,length(win))+repmat(win,length(xcoord),1); 
        xmat = xmat'; 
        pkmeans = mean(ynew(xmat)); 
        ycoord = ynew(xcoord); 
        savename = [filename(1:find(filename=='.')-1) '_col_' num2str(i) '_pkmeans.mat']; 
        save(savename,'xcoord','ycoord','pkmeans');         
        clear xmat pkmeans ycoord xcoord ynew 
        close(gcf); 
    end 
 
else 
    msgbox('No File Selected')  
end 
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APPENDIX G 
 
LAB NOTEBOOK REFERENCES 
 
Figure Date of Experiments Lab Notebook Reference 
5 (top) 
5 (bottom) 
11-24, 11-25, 12-3-05
10-28-04 
GS #4, p.72, 74, 78 
GS #4, p.52 
6 4-8-05 GS #4, p.154 
7 (ELISA) 
7 (FARA) 
6-22-04 
12-4 to 12-7-05 
GS #5, p.36 
GS #5, p.114 
8 6-2 to 6-3-05 GS #5, p.8-11 
11 (low power) 
11 (high power dry) 
11 (high power wet) 
8-17-05 
Dry: 5-17-05 
Wet: 7-21-05 
GS #6, p59-60 
Kelvin #1, p.6 
Kelvin #1, p.109 
12 8-16-05 GS #6, p.56 
13 8-24 to 8-25-05 OneNote, August 2005 
14 (top) 
14 (bottom) 
8-18-05 
8-23-05 
GS #6, p.61 
OneNote, August 2005 
15 8-23 to 8-24-05 OneNote, August 2005 
19 T3D 
19 T3SA+ 
19 T1L 
19 M13K07 
10-26-05 
10-27-05 
10-25-05 
10-24-05 
OneNote, October 2005 
 
Table Date of Experiments Lab Notebook Reference 
6 10-24 to 10-27-05 OneNote, October 2005 
7 10-24 to 10-27-05 OneNote, October 2005 
 
All data and results are organized by date in the “Filament Stuff” folder on Greg’s 
computer.  GenePix images are organized by date in the “Stone” folder on the GenePix 
computer. 
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